Wright Medical 10-K 21 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 29, 2013	Feb. 18, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	29-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'TRNX	'	'
Entity Registrant Name	'Tornier N.V.	'	'
Entity Central Index Key	'0001492658	'	'
Current Fiscal Year End Date	'--12-29	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	48,521,602	'
Entity Public Float	'	'	$481,700,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$56,784	$31,108
Accounts receivable (net of allowance of $5,080 and $4,846, respectively)	55,555	54,192
Inventories	87,011	86,697
Income taxes receivable	'	382
Deferred income taxes	5,601	2,734
Prepaid taxes	14,667	14,752
Prepaid expenses	3,151	2,998
Other current assets	3,756	4,455
Total current assets	226,525	197,318
Instruments, net	63,055	51,394
Property, plant and equipment, net	43,494	37,151
Goodwill	251,540	239,804
Intangible assets, net	117,608	126,594
Deferred income taxes	660	159
Other assets	2,544	1,807
Total assets	705,426	654,227
Current liabilities:	'	'
Short-term borrowing and current portion of long-term debt	1,438	4,595
Accounts payable	17,326	11,526
Accrued liabilities	50,714	44,410
Income taxes payable	397	83
Contingent consideration, current	6,428	'
Deferred income taxes	13	12
Total current liabilities	76,316	60,626
Long-term debt	67,643	115,457
Deferred income taxes	21,489	20,284
Contingent consideration, long-term	6,528	15,265
Other non-current liabilities	7,642	6,516
Total liabilities	179,618	218,148
Shareholders' equity:	'	'
Ordinary shares, €0.03 par value; authorized 175,000,000; issued and outstanding 48,508,612 and 41,728,257 at December 29, 2013 and December 30, 2012, respectively	1,921	1,655
Additional paid-in capital	769,466	660,968
Accumulated deficit	-272,158	-235,732
Accumulated other comprehensive income	26,579	9,188
Total shareholders' equity	525,808	436,079
Total liabilities and shareholders' equity	$705,426	$654,227

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 29, 2013	Dec. 29, 2013	Dec. 30, 2012	Dec. 30, 2012
In Thousands, except Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Statement Of Financial Position [Abstract]	'	'	'	'
Accounts receivable, allowance	$5,080	'	$4,846	'
Ordinary shares, par value	'	€ 0.03	'	€ 0.03
Ordinary shares, authorized	175,000,000	175,000,000	175,000,000	175,000,000
Ordinary shares, issued	48,508,612	48,508,612	41,728,257	41,728,257
Ordinary shares, outstanding	48,508,612	48,508,612	41,728,257	41,728,257

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Income Statement [Abstract]	'	'	'
Revenue	$310,959	$277,520	$261,191
Cost of goods sold	86,172	81,918	74,882
Gross profit	224,787	195,602	186,309
Operating expenses:	'	'	'
Selling, general and administrative	206,851	170,447	161,448
Research and development	22,387	22,524	19,839
Amortization of intangible assets	15,885	11,721	11,282
Special charges	3,738	19,244	892
Total operating expenses	248,861	223,936	193,461
Operating loss	-24,074	-28,334	-7,152
Other income (expense):	'	'	'
Interest income	245	338	550
Interest expense	-7,256	-3,733	-4,326
Foreign currency transaction (loss) gain	-1,820	-473	193
Loss on extinguishment of debt	-1,127	-593	-29,475
Other non-operating (expense) income, net	-45	116	1,330
Loss before income taxes	-34,077	-32,679	-38,880
Income tax (expense) benefit	-2,349	10,935	8,424
Consolidated net loss	($36,426)	($21,744)	($30,456)
Net loss per share:	'	'	'
Basic and diluted	($0.79)	($0.54)	($0.80)
Weighted average shares outstanding:	'	'	'
Basic and diluted	45,826	40,064	38,227

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Consolidated net loss	($36,426)	($21,744)	($30,456)
Unrealized gain (loss) on retirement plans, net of tax	95	-866	-32
Foreign currency translation adjustments	17,296	4,938	-10,160
Comprehensive loss	($19,036)	($17,672)	($40,648)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Cash flows from operating activities:	'	'	'
Consolidated net loss	($36,426)	($21,744)	($30,456)
Adjustments to reconcile consolidated net loss to cash provided by operating activities:	'	'	'
Depreciation and amortization	36,566	30,232	28,107
Impairment of fixed assets	140	2,041	'
Lease termination costs	'	731	'
Intangible impairment	'	4,737	210
Non-cash foreign currency loss (gain)	1,829	-495	298
Deferred income taxes	3,566	-4,506	-11,619
Tax benefit from reversal of valuation allowance	-1,120	-10,700	'
Share-based compensation	8,300	6,830	6,547
Non-cash interest expense and discount amortization	969	524	2,040
Inventory obsolescence	8,447	8,171	4,996
Loss on extinguishment of debt	1,127	593	29,475
Incentive related to new facility lease	'	1,400	'
Acquired inventory step-up	5,908	1,993	'
Gain on reversal of OrthoHelix contingent consideration liability	-5,140	'	'
Other non-cash items affecting earnings	1,095	1,836	-186
Changes in operating assets and liabilities, net of acquisitions:	'	'	'
Accounts receivable	-1,084	-2,188	-4,673
Inventories	-9,186	-3,057	-7,939
Accounts payable and accruals	7,421	87	2,573
Other current assets and liabilities	4,704	-1,526	3,987
Other non-current assets and liabilities	-2,134	65	-194
Net cash provided by operating activities	24,982	14,431	23,166
Cash flows from investing activities:	'	'	'
Acquisition-related cash payments	-10,148	-102,612	'
Purchases of intangible assets	-2,935	-1,410	-3,142
Additions of instruments	-23,805	-11,999	-19,734
Property, plant and equipment lease incentive	'	-1,400	'
Purchases of property, plant and equipment	-10,825	-9,891	-6,599
Proceeds from sale of property, plant and equipment	'	1,517	'
Net cash used in investing activities	-47,713	-125,795	-29,475
Cash flows from financing activities:	'	'	'
Change in short-term debt	-1,000	-8,009	-10,513
Repayments of long-term debt	-54,095	-28,684	-8,147
Repayment of notes payable	'	'	-116,108
Proceeds from issuance of long-term debt	1,796	121,045	5,032
Deferred financing costs	-111	-5,396	-2,731
Issuance of ordinary shares from stock option exercises	21,481	7,710	'
Proceeds from other issuance of ordinary shares	78,952	'	171,577
Net cash provided by financing activities	47,023	86,666	39,110
Effect of exchange rate changes on cash and cash equivalents	1,384	1,100	-2,933
Increase (decrease) in cash and cash equivalents	25,676	-23,598	29,868
Cash and cash equivalents:	'	'	'
Beginning of period	31,108	54,706	24,838
End of period	56,784	31,108	54,706
Non cash investing and financing transactions:	'	'	'
Fixed assets acquired pursuant to capital lease	42	560	640
Capitalized software development costs	1,180	'	'
Supplemental disclosure:	'	'	'
Income taxes paid	1,700	2,937	1,119
Interest paid	$6,043	$2,084	$2,235

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Ordinary Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Balance at Jan. 01, 2011	$270,239	$1,156	$437,307	$15,308	($183,532)
Balance (in shares) at Jan. 01, 2011	'	29,569,000	'	'	'
Net loss attributable to Tornier	-30,456	'	'	'	-30,456
Unrealized loss on retirement plans	-32	'	'	-32	'
Foreign currency translation adjustments	-10,160	'	'	-10,160	'
Initial public offering financing costs	-17,962	'	-17,962	'	'
Issuance of ordinary shares related to initial public offering	179,954	394	179,560	'	'
Issuance of ordinary shares related to initial public offering (in shares)	'	9,471,000	'	'	'
Issuance of ordinary shares related to stock option exercises	3,320	10	3,310	'	'
Issuance of ordinary shares related to stock option exercises ( in shares)	210,000	230,000	'	'	'
Share-based compensation	6,557	'	6,557	'	'
Balance at Jan. 01, 2012	401,460	1,560	608,772	5,116	-213,988
Balance (in shares) at Jan. 01, 2012	'	39,270,000	'	'	'
Net loss attributable to Tornier	-21,744	'	'	'	-21,744
Unrealized loss on retirement plans	-866	'	'	-866	'
Foreign currency translation adjustments	4,938	'	'	4,938	'
Issuances of ordinary shares related to acquisition of OrthoHelix Surgical Designs, Inc.	38,029	75	37,954	'	'
Issuances of ordinary shares related to acquisition of OrthoHelix Surgical Designs, Inc ( in shares).	'	1,941,000	'	'	'
Issuances of ordinary shares related to employee stock purchase plan	170	1	169	'	'
Issuances of ordinary shares related to employee stock purchase plan ( in shares)	'	8,000	'	'	'
Issuances of ordinary shares for restricted stock units	'	2	-2	'	'
Issuances of ordinary shares for restricted stock units ( in shares)	'	50,000	'	'	'
Issuance of ordinary shares related to stock option exercises	7,540	17	7,523	'	'
Issuance of ordinary shares related to stock option exercises ( in shares)	426,000	459,000	'	'	'
Share-based compensation	6,552	'	6,552	'	'
Balance at Dec. 30, 2012	436,079	1,655	660,968	9,188	-235,732
Balance (in shares) at Dec. 30, 2012	41,728,257	41,728,000	'	'	'
Net loss attributable to Tornier	-36,426	'	'	'	-36,426
Unrealized loss on retirement plans	95	'	'	95	'
Foreign currency translation adjustments	17,296	'	'	17,296	'
Secondary offering financing costs	-4,878	'	-4,878	'	'
Issuance of ordinary shares related to initial public offering	83,577	202	83,375	'	'
Issuance of ordinary shares related to initial public offering (in shares)	'	5,175,000	'	'	'
Issuances of ordinary shares related to employee stock purchase plan	254	1	253	'	'
Issuances of ordinary shares related to employee stock purchase plan ( in shares)	'	15,000	'	'	'
Issuances of ordinary shares for restricted stock units	'	4	-4	'	'
Issuances of ordinary shares for restricted stock units ( in shares)	'	98,000	'	'	'
Issuance of ordinary shares related to stock option exercises	21,481	59	21,422	'	'
Issuance of ordinary shares related to stock option exercises ( in shares)	1,454,000	1,493,000	'	'	'
Share-based compensation	8,330	'	8,330	'	'
Balance at Dec. 29, 2013	$525,808	$1,921	$769,466	$26,579	($272,158)
Balance (in shares) at Dec. 29, 2013	48,508,612	48,509,000	'	'	'

Business_Description

Business Description	12 Months Ended
	Dec. 29, 2013
Accounting Policies [Abstract]	'
Business Description	'
	1. Business Description
	Tornier N.V. (Tornier or the Company) is a global medical device company focused on providing solutions to surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot, referred to as “extremity joints.” The Company sells to this surgeon base a broad line of joint replacement, trauma, sports medicine and biologic products to treat extremity joints. In certain international markets, the Company also offers joint replacement products for the hip and knee.
	Tornier’s global corporate headquarters are located in Amsterdam, the Netherlands. The Company also has significant operations located in Bloomington, Minnesota (U.S. headquarters, sales, marketing and distribution and administration), Grenoble, France (OUS headquarters, manufacturing and research and development), Macroom, Ireland (manufacturing), Warsaw, Indiana (research and development) and Medina, Ohio (marketing, research and development). In addition, the Company conducts local sales and distribution activities across 13 sales offices throughout Europe, Asia, Australia and Canada.
	Basis of Presentation
	The Company’s fiscal year-end is generally determined on a 52-week basis consisting of four 13 week quarters and always falls on the Sunday nearest to December 31.
	The consolidated financial statements and accompanying notes present the consolidated results of the Company for each of the fiscal years in the three-year period ended December 29, 2013, December 30, 2012 and January 1, 2012.
	On January 28, 2011, the Company executed a 3-to-1 reverse stock split of the Company’s ordinary shares.
	On January 28, 2011, the Company made a change to its legal form by converting from Tornier B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) to Tornier N.V., a public company with limited liability (naamloze vennootschap).
	In February 2011, the Company completed an initial public offering of 8,750,000 ordinary shares at an offering price of $19.00 per share (before underwriters’ discounts and commissions). The Company received proceeds of approximately $149.2 million (after underwriters’ discounts and commissions of approximately $10.8 million and additional offering related costs of $6.2 million). Net proceeds were used for the retirement of debt, working capital and other general corporate purposes. Additionally, on March 7, 2011, the Company issued an additional 721,274 ordinary shares at an offering price of $19.00 per share (before underwriters’ discounts and commissions) due to the exercise of the underwriters’ overallotment option. The Company received additional net proceeds of approximately $12.8 million (after underwriters’ discounts and commissions of approximately $0.9 million).
	All amounts are presented in U.S. Dollar (“$”), except where expressly stated as being in other currencies, e.g. Euros (“€”).

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 29, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	2. Significant Accounting Policies
	Consolidation
	The consolidated financial statements include the accounts of the Company and all of its wholly and majority owned subsidiaries. In consolidation, all material intercompany accounts and transactions are eliminated.
	Use of Estimates
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (U.S. GAAP) and include amounts that are based on management’s best estimates and judgments. Actual results could differ from those estimates.
	Foreign Currency Translation
	The functional currencies for the Company and all of the Company’s wholly owned subsidiaries are their local currencies. The reporting currency of the Company is the U.S. dollar. Accordingly, the consolidated financial statements of the Company and its international subsidiaries are translated into U.S. dollars using current exchange rates for the consolidated balance sheets and average exchange rates for the consolidated statements of operations and cash flows. Unrealized translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders’ equity. When a transaction is denominated in a currency other than the subsidiary’s functional currency, the Company recognizes a transaction gain or loss in net earnings. Foreign currency transaction (losses) gains included in net earnings were $(1.8) million, $(0.5) million and $0.2 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	Revenue Recognition
	The Company derives revenue from the sale of medical devices that are used by orthopaedic and general surgeons who treat diseases and disorders of extremity joints, including the shoulder, elbow, wrist, hand, ankle and foot, and large joints, including the hip and knee. Revenue is generated from sales to two types of customers: healthcare institutions and stocking distributors, with sales to healthcare institutions representing a majority of the Company’s revenue. Revenue from sales to healthcare institutions is recognized at the time of surgical implantation. Revenue from sales to stocking distributors is recorded at the time the product is shipped to the distributor. These stocking distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at the time of shipment. Stocking distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. In certain circumstances, the Company may accept sales returns from distributors and in certain situations in which the right of return exists, the Company estimates a reserve for sales returns and recognizes the reserve as a reduction of revenue. The Company bases its estimate for sales returns on historical sales and product return information including historical experience and trend information. The Company’s reserve for sales returns has historically been immaterial.
	Shipping and Handling
	Amounts billed to customers for shipping and handling of products are reflected in revenue and are not considered significant. Costs related to shipping and handling of products are expensed as incurred, are included in selling, general and administrative expense, and were $5.7 million, $5.1 million and $5.2 million for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	Cash and Cash Equivalents
	Cash equivalents are highly liquid investments with an original maturity of three months or less. The carrying amount reported in the consolidated balance sheets for cash and cash equivalents is cost, which approximates fair value.
	Accounts Receivable
	Accounts receivable consist of customer trade receivables. The Company maintains an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. The Company makes estimates regarding the future ability of its customers to make required payments based on historical credit experience, delinquency and expected future trends. The majority of the Company’s receivables are from healthcare institutions, many of which are government-funded. The Company’s allowance for doubtful accounts was $5.1 million and $4.8 million at December 29, 2013 and December 30, 2012, respectively. Accounts receivable are written off when it is determined that the accounts are uncollectible, typically upon customer bankruptcy or the customer’s non-response to continued collection efforts.
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. The allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. As of December 29, 2013, there were no customers that accounted for more than 10% of accounts receivable.
	Royalties
	The Company pays royalties to certain individuals and companies that have developed and retain the legal rights to the technology or have assisted the Company in the development of technology or new products. These royalties are based on sales and are reflected as selling, general and administrative expenses in the consolidated statements of operations.
	Inventories
	Inventories, net of reserves for obsolete and slow-moving goods, are stated at the lower of cost or market value. Cost is determined on a first-in, first-out (FIFO) basis. Costs included in the value of inventory that Tornier manufactures include the material costs, direct labor costs and manufacturing and distribution overhead costs. Inventories consist of raw materials, work-in-process and finished goods. Finished goods inventories are held primarily in the United States, several countries in Europe, Canada, Japan and Australia and consist primarily of joint implants and related orthopaedic products. Inventory balances, net of reserves, consist of the following (in thousands):
		December 29,			December 30,
		2013			2012
	Raw materials	$	6,840		$	5,696
	Work in process		9,171			4,933
	Finished goods		71,000			76,068
	Total	$	87,011		$	86,697
	The Company regularly reviews inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incurs charges to write down inventories to their net realizable value. The Company’s review of inventory for excess and obsolete quantities is based primarily on the estimated forecast of future product demand, production requirements, and introduction of new products. The Company recognized $8.4 million, $8.2 million and $5.0 million of expense for excess and obsolete inventory in cost of goods sold during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively. The increase in excess and obsolete charges in 2012 included a $3.0 million charge related to rationalization of products associated with the integration of OrthoHelix into Tornier. Additionally, the Company had $47.8 million and $44.5 million in inventory held on consignment with third-party distributors and healthcare facilities, among others, at December 29, 2013 and December 30, 2012, respectively.
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on estimated useful lives of five to thirty-nine years for buildings and improvements and two to eight years for machinery and equipment. The cost of maintenance and repairs is expensed as incurred. The Company reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset’s carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value.
	For the year ended December 29, 2013, the Company recorded $0.1 million in impairment related to the fixed assets located in Medina, Ohio that the Company is abandoning as part of its OrthoHelix restructuring plan. As a result of the Company’s facilities consolidation initiative in 2012, the Company recorded several fixed asset impairments related to the Company’s facilities in St. Ismier, France, Dunmanway, Ireland, and Stafford, Texas in the aggregate amount of $0.9 million for the year ended December 30, 2012.
	Software Development Costs
	The Company capitalizes certain computer software and software development costs incurred in connection with developing or obtaining computer software for internal use when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs generally include external direct costs of materials and services utilized in developing or obtaining computer software and compensation and related benefits for employees who are directly associated with the software project. Capitalized software costs are included in property, plant and equipment on the Company’s consolidated balance sheet and amortized on a straight-line basis when the software is ready for its intended use over the estimated useful lives of the software, which approximate three to ten years.
	Instruments
	Instruments are surgical tools used by orthopaedic and general surgeons during joint replacement and other surgical procedures to facilitate the implantation of the Company’s products. Instruments are recognized as long-lived assets. Instruments and instrument parts that have not been placed in service are carried at cost, and are included as instruments in progress within instruments, net on the consolidated balance sheets. Once placed in service, instruments are carried at cost, less accumulated depreciation. Depreciation is computed using the straight-line method based on average estimated useful lives. Estimated useful lives are determined principally in reference to associated product life cycles, and average five years. Instrument parts used to maintain the functionality of instruments but do not extend the life of the instruments are expensed as they are consumed and recorded as part of selling, general and administrative expense. The Company reviews instruments for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the assets are less than the assets’ carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. No impairment losses were recognized during the years ended December 29, 2013 and January 1, 2012. The Company recorded impairment charges of $1.0 million during the year ended December 30, 2012 related to instrument sets and components that were impaired as a result of revisions to existing product lines. Instruments included in long-term assets on the consolidated balance sheets are as follows (in thousands):
		December 29,			December 30,
		2013			2012
	Instruments	$	99,754		$	85,869
	Instruments in progress		23,990			18,171
	Accumulated depreciation		(60,689	)		(52,646	)
	Instruments, net	$	63,055		$	51,394
	The Company provides instruments to surgeons for use in surgeries and retains title to the instruments. As instruments are used as tools to assist surgeons, depreciation of instruments is recognized as a selling, general and administrative expense. Instrument depreciation expense was $13.9 million, $12.4 million and $11.0 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	Business Combinations
	For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, generally at their fair values starting in the period when the acquisition is completed. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred.
	Goodwill
	Goodwill is recognized as the excess of the purchase price over the fair value of net assets of businesses acquired. Goodwill is not amortized, but is subject to impairment tests. Based on the Company’s single business approach to decision-making, planning and resource allocation, management has determined that the Company has one reporting unit for the purpose of evaluating goodwill for impairment. The Company performs its annual goodwill impairment test as of the first day of the fourth quarter of its fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Impairment tests are done by qualitatively assessing the likeliness for impairment and then, if necessary, comparing the reporting unit’s fair value to its carrying amount to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill. The fair value of the reporting unit and the implied fair value of goodwill are determined based on widely accepted valuation techniques. No goodwill impairment losses were recorded during the years ended December 29, 2013, December 30, 2012 and January 1, 2012 as the fair value of the reporting unit significantly exceeded its carrying value.
	Intangible Assets
	Intangible assets with an indefinite life, including certain trademarks and trade names, are not amortized, but are tested for impairment annually or whenever events or circumstances indicate that the carrying amount may not be recoverable. Any amount of impairment loss to be recorded would be determined based upon the excess of the asset’s carrying value over its fair value. No impairment losses on indefinite life intangibles were recorded during the years ended December 29, 2013, December 30, 2012 and January 1, 2012. The useful lives of these assets are also assessed annually to determine whether events and circumstances continue to support an indefinite life.
	Intangible assets with a finite life, including developed technology, customer relationships, and patents and licenses, are amortized on a straight-line basis over their estimated useful lives, ranging from one to twenty years. Costs incurred to extend or renew license arrangements are capitalized as incurred and amortized over the shorter of the life of the extension or renewal, or the remaining useful life of the underlying product being licensed. Intangible assets with a finite life are tested for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset’s carrying amount and would be measured as the amount by which the carrying amount of an asset exceeds its fair value. For the year ended December 29, 2013, the Company recognized an impairment charge of $0.1 million related to license intangibles that are no longer being used. For the year ended December 30, 2012, the Company recognized an impairment charge of $4.7 million related to developed technology and customer relationship intangibles whose fair values were negatively impacted by the acquisition of OrthoHelix. The fair value of the intangibles was determined using a discounted cash flow analysis. For the year ended January 1, 2012, the Company recognized an impairment charge of $0.2 million related to developed technology from acquired entities that was no longer being used. For the years ended December 29, 2013 and January 1, 2012, intangible asset impairments are included in amortization of intangible assets in the consolidated statements of operations. For the year ended December 30, 2012, intangible asset impairments are included in special charges on the consolidated statement of operations as they related directly to the acquisition and integration of OrthoHelix.
	Derivative Financial Instruments
	All of the Company’s derivative instruments are economic hedges and are recorded in the accompanying consolidated balance sheets as either an asset or liability and are measured at fair value. The changes in the derivative’s fair value are recognized in earnings as a component of foreign currency transaction gain (loss) in the period in which the change occurred.
	Research and Development
	All research and development costs are expensed as incurred.
	Income Taxes
	Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances for deferred tax assets are recognized if it is more likely than not that some component or all of the benefits of deferred tax assets will not be realized.
	The Company accrues interest and penalties related to unrecognized tax benefits in the Company’s provision for income taxes. In the fiscal years ended December 29, 2013 and December 30, 2012, accrued interest and penalties were $0.3 million and $0.2 million, respectively.
	Other Comprehensive Income (Loss)
	Other comprehensive income (loss) refers to revenues, expenses, gains, and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings, as these amounts are recorded directly as an adjustment to shareholders’ equity. Other comprehensive income (loss) is comprised mainly of foreign currency translation adjustments and unrealized gains (losses) on retirement plans. These amounts are presented in the consolidated statements of comprehensive loss.
	Share-Based Compensation
	The Company accounts for share-based compensation in accordance with Accounting Standards Codification (ASC) Topic 718, Compensation – Stock Compensation, which requires share-based compensation cost to be measured at the grant date based on the fair value of the award and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. The determination of the fair value of share-based payment awards, such as options, is made on the date of grant using an option-pricing model is affected by the Company’s share price, as well as assumptions regarding a number of complex and subjective variables, which include the expected life of the award, the expected share price volatility over the expected life of the award, expected dividend yield and risk-free interest rate.
	New Accounting Pronouncements
	In June 2013, the FASB issued Accounting Standards Update (ASU) 2013-11, Income Taxes (ASC Topic 740), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The ASU requires entities to present unrecognized tax benefits as a decrease in a net operating loss, similar to tax loss or tax credit carryforward if certain criteria are met. The standard clarifies presentation requirements for unrecognized tax benefits but will not alter the way in which entities assess deferred tax assets for realizability. The guidance is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013. The Company will adopt this guidance beginning in the first quarter of 2014. The impact of adoption is not expected to be material.
	In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (ASC Topic 830), Parent’s Accounting for the Cumulative Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. The ASU requires entities to release cumulative translation adjustments to earnings when an entity ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity and the sale or transfer results in the complete or substantially complete liquidation of the foreign entity. The ASU is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013 and is to be applied prospectively. The Company will adopt this guidance in the first quarter of 2014 and will affect the accounting for any future liquidation of foreign subsidiaries.
	In February 2013, the FASB issued ASU 2013-04, Liabilities (ASC Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. The ASU requires an entity that is jointly and severally liable to measure the obligation as the sum of the amount the entity has agreed with co-obligors to pay and any additional amount it expects to pay on behalf of one or more co-obligors. The amendment is effective for the fiscal year, and interim periods with that fiscal year, beginning after December 15, 2013 and should be applied retrospectively. The Company will adopt this guidance in the first quarter of 2014. The impact of adoption is expected to be immaterial.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Dec. 29, 2013
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	3. Fair Value of Financial Instruments
	The Company measures certain assets and liabilities at fair value on a recurring or non-recurring basis based on the application of ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. This requires fair value measurements to be classified and disclosed in one of the following three categories:
	Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.
	Level 2—Assets and liabilities determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
	Level 3—Assets and liabilities that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the asset or liability. The prices are determined using significant unobservable inputs or valuation techniques.
	A summary of the financial assets and liabilities that are measured at fair value on a recurring basis at December 29, 2013 and December 30, 2012 are as follows:
		December 29, 2013			Quoted Prices in		Significant Other		Significant
					Active Markets		Observable Inputs		Unobservable
					(Level 1)		(Level 2)		Inputs (Level 3)
	Cash and cash equivalents	$	56,784		$	56,784	$	—	$	—
	Contingent consideration		(12,956	)		—		—		(12,956	)
	Derivative asset		238			—		238		—
	Total, net	$	44,066		$	56,784	$	238	$	(12,956	)
		December 30, 2012			Quoted Prices in		Significant Other		Significant
					Active Markets		Observable Inputs		Unobservable
					(Level 1)		(Level 2)		Inputs (Level 3)
	Cash and cash equivalents	$	31,108		$	31,108	$	—	$	—
	Contingent consideration		(15,265	)		—		—		(15,265	)
	Derivative asset		274			—		274		—
	Total, net	$	16,117		$	31,108	$	274	$	(15,265	)
	As of December 29, 2013 and December 30, 2012 the Company had a derivative asset with a fair value of $0.2 million and $0.3 million, respectively, with recurring Level 2 fair value measurements. The derivatives are foreign exchange forward contracts and their fair values are based on pricing for similar recently executed transactions. The amount of gain (loss) recognized in foreign exchange loss for the year ended December 29, 2013 and December 30, 2012 related to this derivative is approximately $0.4 million and $0.3 million, respectively. Included in Level 3 fair value measurements as of December 29, 2013 is a $10.4 million contingent consideration liability related to potential earnout payments for the acquisition of OrthoHelix that was completed in October 2012, a $1.9 million contingent consideration liability related to earn-out payments for distributor acquisitions in the United States that occurred throughout 2013, a $0.5 million contingent consideration liability related to potential earnout payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg that was completed in May 2012 and a $0.2 million contingent consideration liability related to potential earnout payments related to the acquisition of a distributor in Australia. Contingent consideration liabilities are carried at fair value and included in contingent consideration (short term and long term) on the consolidated balance sheet. The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates and a discount rate, which are considered significant unobservable inputs as of December 29, 2013. The revenue estimates were based on current management expectations for these businesses and the discount rate used was between 8-11% and was based on the Company’s estimated weighted average cost of capital for each transaction. To the extent that these assumptions were to change, the fair value of the contingent consideration liabilities could change significantly. Included in interest expense on the consolidated statement of operations for the year ended December 29, 2013 is $1.1 million related to the accretion of the contingent consideration. There were no transfers between levels during the year ended December 29, 2013.
	Included in Level 3 fair value measurements as of December 30, 2012 is a $14.5 million contingent consideration liability related to potential earn-out payments for the acquisition of OrthoHelix and a $0.7 million contingent consideration liability related to potential earn-out payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg. The contingent consideration liabilities are carried at fair value, which is determined based on a discounted cash flow analysis that included revenue estimates and a discount rate, which are considered significant unobservable inputs as of December 30, 2012. The revenue estimates were based on then current management expectations for these businesses and the discount rate used as of December 30, 2012 was 8% and was based on the Company’s estimated weighted average cost of capital. Included in interest expense on the consolidated statement of operations for the year ended December 30, 2012 is $0.3 million related to the accretion of the contingent consideration. There were no transfers between levels during the year ended December 30, 2012.
	A rollforward of the level 3 contingent liability for the year ended December 29, 2013 is as follows (in thousands):
	Contingent consideration liability at December 30, 2012	$	15,265
	Additions		3,329
	Fair value adjustments		(5,140	)
	Settlements		(1,640	)
	Interest accretion		1,132
	Foreign currency translation		10
	Contingent consideration at December 29, 2013		12,956
	The Company also has assets and liabilities that are measured at fair value on a non-recurring basis. The Company reviews the carrying amount of its long-lived assets other than goodwill for potential impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. During the year ended December 30, 2012, the Company recognized an intangible impairment of $4.7 million. The impairment was determined using a discounted cash flow analysis. Key inputs into the analysis included estimated future revenues and expenses and a discount rate. The discount rate of 8% was based on the Company’s weighted average cost of capital. These inputs are considered to be significant unobservable inputs and are considered Level 3 fair value measurements. No intangible impairments were recorded for the year ended December 29, 2013.
	During the year ended December 30, 2012, the Company initiated and completed a facilities consolidation initiative that included the closure and consolidation of certain facilities in France, Ireland and the United States, which resulted in the recognition of a $0.9 million impairment charge to write down certain fixed assets to their estimated fair values. The fair value calculations were performed using a cost-to-sell analysis and are considered Level 2 fair value measurements as the key inputs into the calculations included estimated market values of the facilities, which are considered indirect observable inputs. In addition, the Company recorded $0.7 million of lease termination costs for the year ended December 30, 2012 related to the facilities consolidation initiative. The termination costs were determined using a discounted cash flow analysis that included a discount rate assumption, which is based on the credit adjusted risk free interest rate input, and an assumption related to the timing and amount of sublease income. The timing of the sublease income is a significant unobservable input and thus is considered a Level 3 fair value measurement. As of December 29, 2013, the value of this liability was approximately $0.4 million.
	As of December 29, 2013 and December 30, 2012, the Company had short-term and long-term debt of $69.1 million and $120.1 million, respectively, the vast majority of which was variable rate debt. The fair value of the Company’s debt obligations approximates carrying value as a result of its variable rate term and would be considered a Level 2 measurement.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 29, 2013
Business Combinations [Abstract]	'
Business Combinations	'
	4. Business Combinations
	On October 4, 2012, the Company completed the acquisition of 100% of the outstanding common stock of OrthoHelix Surgical Designs, Inc which further expanded the Company’s lower extremity joints and trauma product portfolio. Under the terms of the agreement, the Company acquired the assets and assumed certain liabilities of OrthoHelix for an aggregate purchase price of $152.6 million, including $100.4 million in cash, the equivalent of $38.0 million in Tornier ordinary shares based on the closing share price on the date of acquisition, and $14.2 million related to the fair value of additional contingent consideration of up to $20.0 million. The contingent consideration is payable in future periods based on growth of the lower extremity joints and trauma revenue category.
	The OrthoHelix acquisition was accounted for as an acquisition of a business; and, accordingly, the financial results have been included in the Company’s consolidated results of operations from the date of acquisition. The allocation of the total purchase price to the net tangible and identifiable intangible assets was based on their estimated fair values as of the acquisition date. The excess of the purchase price over the identifiable intangible and net tangible assets in the amount of $105.9 million was allocated to goodwill, which is not deductible for tax purposes. Qualitatively, the three largest components of goodwill include: (1) expansion into international markets; (2) the relationships between the Company’s sales representatives and physicians; and (3) the development of new product lines and technology.
	The following represents the allocation of the purchase price:
		Purchase Price
		Allocation
		(In Thousands)
	Goodwill	$	105,904
	Other intangible assets		40,600
	Tangible assets acquired and liabilities assumed:
	Accounts receivable		4,330
	Inventory		12,033
	Other assets		776
	Instruments, net		4,475
	Accounts payable and accrued liabilities		(3,606	)
	Deferred income taxes		(11,900	)
	Other long-term debt		(16	)
	Total purchase price	$	152,596
	Acquired identifiable intangible assets are amortized on a straight-line basis over their estimated useful lives. The following table represents components of these identifiable intangible assets and their estimated useful lives at the acquisition date:
		Fair Value			Estimated Useful
		(In Thousands)			Life
					(In Years)
	Developed technology	$	35,500			10
	In-process research and development		3,500			N/A
	Trademarks and trade names		1,500			3
	Non-compete agreements		100			3
	Total identifiable intangible assets	$	40,600
	Of the $3.5 million in in-process research and development, three of the four projects have been completed and are included in developed technology as of December 29, 2013.
	The estimated fair value of the intangible assets acquired was determined by the Company with the assistance of a third-party valuation expert. The Company used an income approach to measure the fair value of the developed technology and in-process research and development based on the multi-period excess earnings method, whereby the fair value is estimated based upon the present value of cash flows that the applicable asset is expected to generate. The Company used an income approach to measure the fair value of the trademarks based upon the relief from royalty method, whereby the fair value is estimated based upon discounting the royalty savings as well as any tax benefits related to ownership to a present value. The Company used an income approach to measure the fair value of non-compete agreements, based on the incremental income method, whereby value is estimated by discounting the cash flow differential as well as any tax benefits related to ownership to a present value. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 measurements under the fair value hierarchy. The significant unobservable inputs include the discount rate of 8% which was based on the Company’s estimate of its weighted cost of capital.
	Pro forma results of operations (unaudited) of the Company for the years ended December 30, 2012 and January 1, 2012, as if the acquisition had occurred on January 3, 2011, are as follows:
		Year Ended			Year Ended
		December 30,			January 1,
		2012			2012
	Revenue	$	298,051		$	283,370
	Net loss		(31,390	)		(43,155	)
	Basic and diluted net loss per share	$	(0.75	)	$	(1.07	)
	The pro forma results of operations are not necessarily indicative of future operating results. Included in the consolidated statement of operations for the year ended December 30, 2012 are approximately $8.0 million of revenue and $1.8 million of net loss related to the operations of OrthoHelix subsequent to the transaction closing.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 29, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	5. Property, Plant and Equipment
	Property, plant and equipment balances are as follows (in thousands):
		December 29,			December 30,
		2013			2012
	Land	$	1,886		$	1,830
	Building and improvements		14,255			12,908
	Machinery and equipment		31,192			25,767
	Furniture, fixtures and office equipment		29,371			26,541
	Software		5,511			4,729
	Construction in progress		5,628			2,148
			87,843			73,923
	Accumulated depreciation		(44,349	)		(36,772	)
	Property, plant and equipment, net	$	43,494		$	37,151
	Depreciation expense recorded on property, plant and equipment was $6.8 million, $6.1 million and $6.0 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	For the year ended December 29, 2013, the Company recognized $0.1 million of fixed asset impairments related to the OrthoHelix integration. As a result of the facilities consolidation initiative, the Company recorded several fixed asset impairments during 2012 related to the Company’s facilities in St. Ismier, France, Dunmanway, Ireland, and Stafford, Texas in the aggregate amount of $0.9 million for year ended December 30, 2012. Additionally, the Company recorded $0.1 million in impairments related to certain distribution channel changes in Europe in 2012. These changes are reflected in related fixed asset categories above. These impairments were recorded in special charges, a component of operating expenses, in the consolidated statements of operations for the years ended December 29, 2013 and December 30, 2012. See Note 18 for further description of the facilities consolidation initiative.
	Included in construction in progress is $5.6 million of software development costs, primarily related to the Company’s development of an enterprise resource planning system.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 29, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	6. Goodwill and Other Intangible Assets
	The following table summarizes the changes in the carrying amount of goodwill for the years ended December 29, 2013 and December 30, 2012 (in thousands):
	Balance at January 1, 2012	$	130,544
	Contingent payment on acquisition		1,193
	Goodwill acquired in acquisitions		106,654
	Foreign currency translation		1,413
	Balance at December 30, 2012	$	239,804
	Goodwill acquired in acquisitions		8,239
	Foreign currency translation		3,497
	Balance at December 29, 2013	$	251,540
	The goodwill balance at December 29, 2013 contains $16.8 million of goodwill that qualifies for future tax deductions.
	The components of identifiable intangible assets are as follows (in thousands):
		Gross		Accumulated			Net Value
		Value		Amortization
	Balances at December 29, 2013
	Intangible assets subject to amortization:
	Developed technology	$	112,782	$	(44,161	)	$	68,621
	Customer relationships		61,783		(30,155	)		31,628
	Licenses		6,810		(4,004	)		2,806
	In-process research and development		400		—			400
	Other		6,624		(2,431	)		4,193
	Intangible assets not subject to amortization:
	Tradename		9,960		—			9,960
	Total	$	198,359	$	(80,751	)	$	117,608
		Gross		Accumulated			Net Value
		Value		Amortization
	Balances at December 30, 2012
	Intangible assets subject to amortization:
	Developed technology	$	108,274	$	(34,114	)	$	74,160
	Customer relationships		59,212		(24,634	)		34,578
	Licenses		5,525		(2,927	)		2,598
	In-process research and development		3,200		—			3,200
	Other		3,923		(1,357	)		2,566
	Intangible assets not subject to amortization:
	Tradename		9,492		—			9,492
	Total	$	189,626	$	(63,032	)	$	126,594
	During the year ended December 29, 2013, the Company acquired certain assets of its distributor in Canada for $3.3 million, which included $0.5 million in potential earn-out payments, which were subsequently paid. The purchase accounting for this transaction resulted in an increase in intangible assets of $0.5 million, in the form of customer relationships and non-compete agreements, and an increase in goodwill of $0.3 million. Additionally, during the year ended December 29, 2013, the Company acquired certain assets of a distributor in the United Kingdom for $1.0 million, which included $0.1 million in potential earn-out payments, which were subsequently paid. The purchase accounting for this transaction resulted in an increase in intangible assets of $0.1 million in the form of customer relationships. In addition, during the year ended December 29, 2013, the Company acquired certain assets of a distributor in Australia for $2.6 million, which included $0.2 million in potential earn-out payments. The purchase accounting for this transaction resulted in an increase in intangible assets of $0.1 million in the form of non-compete agreements and an increase in goodwill of $1.4 million. Also during the year ended December 29, 2013, the Company acquired certain U.S. distributors and independent sales agencies. The purchase accounting for these U.S. distributor transactions resulted in $2.2 million of intangible assets, primarily non-compete agreements and an increase in goodwill of $6.7 million.
	During the year ended December 30, 2012, the Company acquired its exclusive distributor in Belgium and Luxembourg for $3.5 million, which included a $1.0 million earn-out. The purchase accounting for this transaction resulted in an increase in intangible assets of $3.0 million and an increase in goodwill of $0.8 million for the year ended December 30, 2012. Additionally, the Company acquired OrthoHelix on October 4, 2012 which resulted in the recording of additional goodwill of $105.9 million and additional intangible assets of $40.6 million for the year ended December 30, 2012. See Note 4 for further details on the acquisition of OrthoHelix.
	For the year ended December 29, 2013, the Company recognized an impairment charge of $0.1 million related to license intangibles that are no longer being used. For the year ended December 30, 2012, the Company recognized an impairment charge of $4.7 million related to intangibles where the carrying value was greater than the fair value of the intangibles due to a reduction in forecasted revenue from the products that related to the intangible as a result of acquiring similar products as part of the OrthoHelix acquisition. For the year ended January 1, 2012, the Company recognized an impairment charge of $0.2 million related to developed technology from acquired entities that is no longer being used.
	All finite-lived intangible assets have been assigned an estimated useful life and are amortized on a straight-line basis over the number of years that approximates the assets’ respective useful lives (ranging from one to twenty years). Included in other intangibles are non-compete agreements and patents. The weighted-average amortization periods, by major intangible asset class, are as follows:
		Weighted-Average
		Amortization Period
		(In Years)
	Developed technology		12
	Customer relationships		13
	Licenses		5
	In-process research and development		—
	Other		3
	Total amortization expense for finite-lived intangible assets was $15.9 million, $11.6 million and $11.3 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively. Amortization expense is recorded as amortization of intangible assets in the consolidated statements of operations. Estimated annual amortization expense for fiscal years ending 2014 through 2018 is as follows (in thousands):
		Amortization Expense
	2014	$	16,866
	2015		16,420
	2016		14,213
	2017		13,299
	2018		12,475

Accrued_Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 29, 2013
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	7. Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		December 29, 2013		December 30, 2012
	Accrued payroll and related expenses	$	21,499	$	16,521
	Accrued royalties		9,169		9,001
	Accrued sales and use tax		4,727		2,022
	Accrued agent commissions		4,554		5,266
	Other accrued liabilities		10,765		11,599
		$	50,714	$	44,410

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 29, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	8. Long-Term Debt
	A summary of long-term debt is as follows (in thousands):
		December 29,			December 30,
		2013			2012
	Lines of credit and overdraft arrangements	$	—		$	1,000
	Mortgages		4,993			3,719
	Bank term debt		61,769			113,135
	Shareholder debt		2,319			2,198
	Total debt		69,081			120,052
	Less current portion		(1,438	)		(4,595	)
	Long-term debt	$	67,643		$	115,457
	Aggregate maturities of debt for the next five years are as follows (in thousands):
	2014	$	1,438
	2015		1,275
	2016		1,447
	2017		61,406
	2018		649
	Thereafter		2,866
	Lines of Credit
	On October 4, 2012, the Company, and one of its U.S. operating subsidiaries, Tornier, Inc. (Tornier USA), entered into a credit agreement with Bank of America, N.A., as Administrative Agent, SG Americas Securities, LLC, as Syndication Agent, BMO Capital Markets and JPMorgan Chase Bank, N.A., as Co-Documentation Agents, Merrill Lynch, Pierce, Fenner & Smith Incorporated and SG Americas Securities, LLC, as Joint Lead Arrangers and Joint Bookrunners, and the other lenders party thereto. The credit facility included a senior secured revolving credit facility to Tornier USA denominated at the election of Tornier USA, in U.S. dollars, Euros, pounds, sterling and yen in an aggregate principal amount of up to the U.S. dollar equivalent of $30.0 million. Funds available under the revolving credit facility may be used for general corporate purposes. Loans under the revolving credit facility bear interest at (a) the alternate base rate (if denominated in U.S. dollars), equal to the greatest of (i) the prime rate in effect on such day, (ii) the federal funds rate in effect on such day plus 1/2 of 1%, and (iii) the adjusted LIBO rate plus 1%, plus in the case of each of (i)-(iii) above, an applicable rate of 2.00% or 2.25% (depending on the Company’s total net leverage ratio as defined in its credit agreement), or (b) in the case of a eurocurrency loan (as defined in the credit agreement), at the applicable adjusted LIBO rate for the relevant interest period plus an applicable rate of 3.00% or 3.25% (depending on the Company’s total net leverage ratio), plus the mandatory cost (as defined in the credit agreement) if such loan is made in a currency other than U.S. dollars or from a lending office in the United Kingdom or a participating member state (as defined in the credit agreement). Additionally, the Company is subject to a 0.5% interest rate related to the unfunded balance on the line of credit. There was no outstanding amount under the line of credit as of December 29, 2013. As of December 30, 2012, the outstanding balance related to this line of credit was $1.0 million. The term of the line of credit ends in October 2017.
	The Company’s European subsidiaries had established unsecured bank overdraft arrangements prior to 2012. This debt was paid off in 2012 and the Company recorded a loss on extinguishment of debt of $0.6 million related to prepayment fees and penalties.
	Mortgages
	The Company has mortgages secured by an office building in Montbonnot, France. These mortgages had an outstanding balance of $5.0 million and $3.7 million at December 29, 2013 and December 30, 2012, respectively, and bear fixed annual interest rates of 2.55%-4.9%.
	Bank Term Debt
	In addition to the senior secured revolving credit facility discussed above, the credit agreement entered into on October 4, 2012 also provided for an aggregate credit commitment to Tornier USA of $115.0 million, consisting of: (1) a senior secured term loan facility to Tornier USA denominated in dollars in an aggregate principal amount of up to $75.0 million; (2) a senior secured term loan facility to Tornier USA denominated in Euros in an aggregate principal amount of up to the U.S. dollar equivalent of $40.0 million. The borrowings under the term loan facilities were used to pay the cash consideration for the OrthoHelix acquisition, and fees, costs and expenses incurred in connection with the acquisition and the credit agreement and to repay prior existing indebtedness of the Company and its subsidiaries. The term loans mature in October 2017. In the second quarter of 2013, the $40.0 million senior secured term loan facility denominated in Euros was repaid in full. As part of the repayment, the Company recorded $1.1 million loss on extinguishment of debt related to the write-off of the corresponding deferred financing costs. Additionally, in June 2013, the Company repaid $10.5 million of the senior secured U.S. dollar denominated loan. Amounts recorded in interest expense related to the amortization of the debt discount were approximately $1.0 million for the year ended December 29, 2013.
	Borrowings under these facilities within the credit agreement as of December 29, 2013 and December 30, 2012 were as follows:
		December 29,			December 30,
		2013			2012
	Senior secured U.S. dollar term loan	$	64,031		$	75,925
	Senior secured Euro term loan		—			40,772
	Debt discount		(3,157	)		(5,138	)
	Total	$	60,874		$	111,559
	The USD term facility bears interest at (a) the alternate base rate (if denominated in U.S. dollars), equal to the greatest of (i) the prime rate in effect on such day, (ii) the federal funds rate in effect on such day plus 1/2 of 1%, and (iii) the adjusted LIBO rate, with a floor of 1% (as defined in the new credit agreement) plus 1%, plus in the case of each of (i)-(iii) above, an applicable rate of 2.00% or 2.25% (depending on the Company’s total net leverage ratio as defined in the Company’s credit agreement), or (b) in the case of a eurocurrency loan (as defined in the Company’s credit agreement), at the applicable adjusted LIBO rate for the relevant interest period plus an applicable rate of 3.00% or 3.25% (depending on the Company’s total net leverage ratio), plus the mandatory cost (as defined in the credit agreement) if such loan is made in a currency other than U.S. dollars or from a lending office in the United Kingdom or a participating member state (as defined in the credit agreement).
	The credit agreement, including the term loan and the revolving line of credit, contains covenants, including financial covenants which require the Company to maintain minimum interest coverage, annual capital expenditure limits and maximum total net leverage ratios, and customary events of default. The obligations under the credit agreement are guaranteed by the Company, Tornier USA and certain other specified subsidiaries of the Company, and subject to certain exceptions, are secured by a first priority security interest in substantially all of the assets of the Company and certain specified existing and future subsidiaries of the Company. Additionally, the credit agreement includes a restriction on the Company’s ability to pay dividends. The Company was in compliance with all covenants as of December 29, 2013.
	Also included in bank term debt is $0.9 million and $1.6 million related to capital leases at December 29, 2013 and December 30, 2012, respectively. See Note 14 for further details.
	Shareholder Debt
	In 2008, one of the Company’s 51%-owned and consolidated subsidiaries borrowed $2.2 million from a member of the Company’s board of directors who is also a 49% owner of the consolidated subsidiary. This loan was used to partially fund the purchase of real estate in Grenoble, France, to be used as a manufacturing facility. Interest on the debt is variable based on three-month Euro Libor rate plus 0.5% and has no stated term. The outstanding balance on this debt was $2.3 and $2.2 million as of December 29, 2013 and December 30, 2012, respectively. The non-controlling interest in this subsidiary is deemed immaterial to the consolidated financial statements.

Retirement_and_Postretirement_

Retirement and Postretirement Benefit Plans	12 Months Ended
	Dec. 29, 2013
Compensation And Retirement Disclosure [Abstract]	'
Retirement and Postretirement Benefit Plans	'
	9. Retirement and Postretirement Benefit Plans
	The Company’s French subsidiary is required by French government regulations to offer a plan to its employees that provides certain lump-sum retirement benefits. This plan qualifies as a defined benefit retirement plan. The French regulations do not require funding of this liability in advance and as a result there are no plan assets associated with this defined-benefit plan. The Company has an unfunded liability of $2.8 million and $2.5 million recorded at December 29, 2013 and December 30, 2012, respectively, for future obligations under the plan that is included in other noncurrent liabilities on the consolidated balance sheet. The government mandated discount rate increased from 2.8% as of December 30, 2012 to 3.0% at December 29, 2013, which resulted in a $0.1 million unrealized gain recorded as a component of other comprehensive loss for the year ended December 29, 2013. For the year ended December 30, 2012, the discount rate decreased from 4.7% to 2.8%, which resulted in a $0.9 million unrealized loss which was recorded as a component of other comprehensive loss. The related periodic benefit expense was immaterial in all periods presented.

Derivative_Instruments

Derivative Instruments	12 Months Ended
	Dec. 29, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Instruments	'
	10. Derivative Instruments
	The Company’s operations outside the United States are significant. As a result, the Company has foreign exchange exposure on transactions denominated in currencies that are different than the functional currency in certain legal entities. Starting in 2012, the Company began entering into forward contracts to manage its exposure to foreign currency transaction gains (losses). As it relates to one of the Company’s U.S. operating entities, Tornier Inc., the Company has entered into forward contracts to manage the foreign currency exposures to the Euro. As it relates to the Company’s French operating entity, Tornier SAS, the Company has entered into forward contracts to manage the foreign currency exposure to the Australian Dollar, British Pound, Canadian Dollar, Japanese Yen, Swiss Franc and U.S. Dollar. Forward contracts are recorded on the consolidated balance sheet at fair value. At December 29, 2013, the Company had foreign currency forward contracts outstanding with a fair value of $0.2 million recorded within other current assets on the consolidated balance sheet. These contracts are accounted for as economic hedges and accordingly, changes in fair value are recognized in earnings. The net gain (loss) on foreign exchange forward contracts is recognized in foreign currency transaction gain (loss). For the years ended December 29, 2013 and December 30, 2012, the Company recognized gains of $0.4 million and $0.3 million, respectively related to these forward currency contracts.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 29, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	11. Income Taxes
	The components of earnings (loss) before taxes for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, consist of the following (in thousands):
		December 29,			December 30,			January 1,
		2013			2012			2012
	United States loss	$	(33,204	)	$	(19,858	)	$	(2,631	)
	Rest of the world loss		(873	)		(12,821	)		(36,249	)
	Loss before taxes	$	(34,077	)	$	(32,679	)	$	(38,880	)
	The income tax benefit (provision) for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, consists of the following (in thousands):
		December 29,			December 30,			January 1,
		2013			2012			2012
	Current (provision) benefit:
	United States	$	(94	)	$	(150	)	$	(327	)
	Rest of the world		(3,513	)		(2,523	)		(3,140	)
	Deferred (provision) benefit		1,258			13,608			11,891
	Total income tax (provision) benefit	$	(2,349	)	$	10,935		$	8,424
	A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, is as follows:
		December 29,			December 30,			January 1,
		2013			2012			2012
	Income tax provision at U.S. statutory rate		34	%		34	%		34	%
	Release of valuation allowance		3.3			32.8			—
	Change in valuation allowance		(38.6	)		(33.4	)		(10.1	)
	Tax benefit from disregarded entity		1.8			1.7			6.4
	State and local taxes		(4.7	)		2.6			(0.4	)
	Tax deductible IPO costs		2			1.7			—
	Other foreign taxes		(3.5	)		(3.5	)		(2.0	)
	Unrecognized interest deduction		—			—			(0.5	)
	Contingent consideration adjustment to market value		4.1			—			—
	Stock option cancellation		(8.1	)
	Impact of foreign income tax rates		2.1			(2.5	)		(6.9	)
	Non-deductible expenses		(1.1	)		(1.8	)		(0.6	)
	Other		1.8			1.9			1.7
	Total		(6.9	)%		33.5	%		21.6	%
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.
	The components of deferred taxes for the years ended December 29, 2013 and December 30, 2012, consist of the following (in thousands):
		December 29,			December 30,
		2013			2012
	Deferred tax assets:
	Net operating loss and tax credit carryforwards	$	41,456		$	27,924
	Inventory		7,294			4,960
	Exchange rate changes		102			223
	Stock options		7,082			9,715
	Accruals and other provisions		6,161			5,067
	Total deferred tax assets		62,095			47,889
	Less: valuation allowance		(40,441	)		(30,011	)
	Total deferred tax assets after valuation allowance		21,654			17,878
	Deferred tax liabilities:
	Intangible assets		(33,553	)		(33,248	)
	Depreciation		(3,342	)		(2,033	)
	Total deferred tax liabilities		(36,895	)		(35,281	)
	Total net deferred tax liabilities	$	(15,241	)	$	(17,403	)
	In 2012, in connection with the acquisition of OrthoHelix, the Company recorded deferred tax liabilities of $11.9 million, which included $10.7 million related to amortizable intangible assets and $1.2 million related to indefinite-lived acquired in-process research and development. The deferred tax liabilities of $10.7 million related to the amortizable intangibles reduces the Company’s net deferred tax assets by a like amount and in a manner that provides predictable future taxable income over the asset amortization period. As a result, the Company reduced its pre-acquisition deferred tax asset valuation allowance in 2012 by $10.7 million, which has been reflected as an income tax benefit in the consolidated statements of operations. Although the deferred tax liability of $1.2 million related to acquired in-process research and development also reduces the net deferred tax assets by a like amount, it does so in a manner that does not provide predictable future taxable income because the related asset is indefinite-lived. Therefore, the deferred tax asset valuation allowance was not reduced as a result of this item.
	The Company had $40.4 million, $30.0 million and $29.8 million of valuation allowance recorded at December 29, 2013, December 30, 2012 and January 1, 2012, respectively. If any amounts of valuation allowance reverse, the reversals would be recognized in the income tax provision in the period of reversal. The Company recognized income tax expense from valuation allowance increases of $10.4 million (an increase in the valuation allowance of $11.5 million netted against a $1.1 million reversal of valuation allowance from the OrthoHelix acquisition), $0.2 million (an increase in the valuation allowance of $10.9 million netted against a $10.7 million reversal of valuation allowance from the OrthoHelix acquisition) and $2.9 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	Net operating loss carryforwards totaling approximately $128.8 million at December 29, 2013, of which $82.0 million relates to the United States and $50.0 million relates to jurisdictions outside the United States, are available to reduce future taxable earnings of the Company’s consolidated U.S. subsidiaries and certain European subsidiaries, respectively. These net operating loss carryforwards include $6.0 million with no expiration date; the remaining carryforwards have expiration dates between 2015 and 2033.
	The Company has recorded a long-term income tax liability of approximately $3.1 million and $2.6 million at December 29, 2013 and December 30, 2012, respectively, related to uncertain tax positions from unclosed tax years in certain of its subsidiaries. These amounts represent the Company’s best estimate of the potential additional tax liability related to these uncertain positions. To the extent that the results of any future tax audits differ from the Company’s estimate, the impact of these differences will be reported as adjustments to income tax expense.
	The total amount of net unrecognized tax benefits that, if recognized, would affect the tax rate was $6.4 million at December 29, 2013. The Company files income tax returns in the U.S. federal jurisdiction and in various U.S. state and foreign jurisdictions. The Company is not currently under examination by any U.S. federal, state, or non-U.S. tax authorities. If any examinations were initiated, the Company would not expect the results of these examinations to have a material impact on its consolidated financial statements in future years.
	A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows (in thousands):
	Gross unrecognized tax benefits at January 1, 2012	$	5,232
	Increase for tax positions in prior years		2,282
	Decrease for tax positions in prior years		—
	Increase for tax positions in current year		306
	Foreign currency translation		89
	Gross unrecognized tax benefits at December 30, 2012	$	7,909
	Increase for tax positions in prior years		58
Decrease for tax positions in prior years		—
Settlements		(2,094	)
Increase for tax positions in current year		307
Foreign currency translation		236
Gross unrecognized tax benefits at December 29, 2013	$	6,416

Capital_Stock_and_Earnings_Per

Capital Stock and Earnings Per Share	12 Months Ended
	Dec. 29, 2013
Earnings Per Share [Abstract]	'
Capital Stock and Earnings Per Share	'
	12. Capital Stock and Earnings Per Share
	The Company had 48.5 million and 41.7 million ordinary shares issued and outstanding as of December 29, 2013 and December 30, 2012, respectively.
	In 2013, the Company completed a secondary offering for the issuance of 5,175,000 shares of common stock that resulted in net proceeds to the Company of $78.7 million.
	The Company had outstanding options to purchase 2.6 million, 3.8 million and 4.2 million ordinary shares at December 29, 2013, December 30, 2012 and January 1, 2012, respectively. The Company also had 0.6 million, 0.4 million and 0.2 million restricted stock units outstanding at December 29, 2013, December 30, 2012 and January 1, 2012, respectively. Outstanding options to purchase ordinary shares and restricted stock units representing an aggregate of 3.2 million, 4.2 million and 4.4 million shares are not included in diluted earnings per share for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively, because the Company recorded a net loss in all periods and, therefore, including these instruments would be anti-dilutive.

Segment_and_Geographic_Data

Segment and Geographic Data	12 Months Ended
	Dec. 29, 2013
Segment Reporting [Abstract]	'
Segment and Geographic Data	'
	13. Segment and Geographic Data
	The Company has one reportable segment, orthopaedic products, which includes the design, manufacture, marketing and sales of joint implants and other related products. The Company’s geographic regions consist of the United States, France and other international areas. Long-lived assets are those assets located in each region. Revenues attributed to each region are based on the location in which the products were sold.
	Revenue by geographic region is as follows (in thousands):
		Year Ended
		December 29, 2013		December 30, 2012		January 1, 2012
	Revenue by geographic region:
	United States	$	182,104	$	156,750	$	141,496
	France		58,173		52,737		55,438
	Other international		70,682		68,033		64,257
	Total	$	310,959	$	277,520	$	261,191
	Revenue by product category is as follows (in thousands):
		Year Ended
		December 29,		December 30,		January 1,
		2013		2012		2012
	Revenue by product type:
	Upper extremity joints and trauma	$	184,457	$	175,242	$	164,064
	Lower extremity joints and trauma		58,747		34,109		26,033
	Sports medicine and biologics		14,752		15,526		14,779
	Total extremities		257,956		224,877		204,876
	Large joints and other		53,003		52,643		56,315
	Total	$	310,959	$	277,520	$	261,191
	Long-lived tangible assets, including instruments and property, plant and equipment are as follows (in thousands):
		December 29,		December 30,		January 1,
		2013		2012		2012
	Long-lived assets:
	United States	$	40,032	$	31,342	$	25,221
	France		45,909		39,764		40,564
	Other international		20,608		17,439		16,915
	Total	$	106,549	$	88,545	$	82,700

Leases

Leases	12 Months Ended
	Dec. 29, 2013
Leases [Abstract]	'
Leases	'
	14. Leases
	Future minimum rental commitments under non-cancelable operating leases in effect as of December 29, 2013 are as follows (in thousands):
	2014	$	5,410
	2015		4,500
	2016		3,535
	2017		3,286
	2018		3,050
	Thereafter		8,362
	Total	$	28,143
	Operating leases include copiers, automobiles and property leases and have maturity dates between 2014 and 2022. Total rent expense for the years ended December 29, 2013, December 30, 2012 and January 1, 2012 was $5.8 million, $4.8 million and $4.0 million, respectively.
	Future lease payments under capital leases are as follows (in thousands):
	2014	$	461
	2015		269
	2016		114
	2017		70
	Total minimum lease payments		914
	Less amount representing interest		(67	)
	Present value of minimum lease payments		847
	Current portion		(448	)
	Long-term portion	$	399
	Fixed assets that are recorded as capital lease assets consist of machinery and equipment, and have a carrying value of $1.7 million ($2.5 million gross value, less $0.8 million accumulated depreciation) and $2.6 million ($3.4 million gross value, less $0.8 million accumulated depreciation) at December 29, 2013 and December 30, 2012, respectively. Amortization of capital lease assets is included in depreciation expense in the consolidated financial statements.

Certain_Relationships_and_Rela

Certain Relationships and Related-Party Transactions	12 Months Ended
	Dec. 29, 2013
Related Party Transactions [Abstract]	'
Certain Relationships and Related-Party Transactions	'
	15. Certain Relationships and Related-Party Transactions
	The Company leases all of its approximately 55,000 square feet of manufacturing facilities and approximately 52,000 square feet of office space located in Montbonnot, France, from Alain Tornier (Mr. Tornier), who is a current shareholder and member of the Company’s board of directors. Annual lease payments to Mr. Tornier amounted to $1.1 million, $1.6 million and $1.9 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	On July 29, 2008, the Company formed a real estate holding company (SCI Calyx) together with Mr. Tornier. SCI Calyx is owned 51% by the Company and 49% by Mr. Tornier. SCI Calyx was initially capitalized by a contribution of capital of €10,000 funded 51% by the Company and 49% by Mr. Tornier. SCI Calyx then acquired a combined manufacturing and office facility in Montbonnot, France, for approximately $6.1 million. The manufacturing and office facility acquired was to be used to support the manufacture of certain of the Company’s current products and house certain operations already located in Montbonnot, France. This real estate purchase was funded through mortgage borrowings of $4.1 million and $2.0 million cash borrowed from the two current shareholders of SCI Calyx. The $2.0 million cash borrowed from the SCI Calyx shareholders originally consisted of a $1.0 million note due to Mr. Tornier and a $1.0 million note due to Tornier SAS, which is the Company’s wholly owned French operating subsidiary. Both of the notes issued by SCI Calyx bear annual interest at the three-month Euro Libor rate plus 0.5% and have no stated term. During 2010, SCI Calyx borrowed approximately $1.4 million from Mr. Tornier in order to fund on-going leasehold improvements necessary to prepare the Montbonnot facility for its intended use. This cash was borrowed under the same terms as the original notes. On September 3, 2008, Tornier SAS, the Company’s French operating subsidiary, entered into a lease agreement with SCI Calyx relating to these facilities. The agreement, which terminates in 2018, provides for an annual rent payment of €440,000, which has subsequently been increased and is currently €904,908 annually. As of December 29, 2013, future minimum payments under this lease were €4.3 million in the aggregate. As of December 29, 2013, SCI Calyx had related-party debt outstanding to Mr. Tornier of $2.3 million. The SCI Calyx entity is consolidated by the Company, and the related real estate and liabilities are included in the consolidated balance sheets.
	Since 2006, Tornier SAS has entered into various lease agreements with entities affiliated with Mr. Tornier or members of his family. On December 29, 2007, Tornier SAS entered into a lease agreement with Mr. Tornier and his spouse, relating to the Company’s museum in Saint Villa, France. The agreement provides for a term through May 30, 2015 and an initial annual rent payment of €28,500, which was subsequently increased to €36,095. On December 29, 2007, Tornier SAS entered into a lease agreement with Animus SCI, relating to the Company’s facilities in Montbonnot Saint Martin, France. On August 18, 2012, the parties amended the lease agreement to extend the term until May 31, 2022 and reduce the annual rent. The amended agreement provides for an initial annual rent payment of €279,506, which was subsequently increased to €288,564. Animus SCI is wholly owned by Mr. Tornier. On February 6, 2008, Tornier SAS entered into a lease agreement with Balux SCI, effective as of May 22, 2006, relating to the Company’s facilities in Montbonnot Saint Martin, France. On August 18, 2012, the parties amended the lease agreement to extend the term until May 31, 2022 and reduce the annual rent. The amended agreement provides for an initial annual rent payment of €252,254, which was subsequently increased to €548,465. Balux SCI is wholly owned by Mr. Tornier and his sister, Colette Tornier. As of December 29, 2013, future minimum payments under all of these agreements were €8.1 million in the aggregate.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 29, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation	'
	16. Share-Based Compensation
	Share-based awards are granted under the Tornier N.V. 2010 Incentive Plan, as amended and restated (2010 Plan). This plan allows for the issuance of up to 7.7 million new ordinary shares in connection with the grant of a combination of potential share-based awards, including stock options, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate. To date, only options to purchase ordinary shares (options) and restricted stock units (RSUs) have been awarded. Both types of awards generally have graded vesting periods of four years and the options expire ten years after the grant date. Options are granted with exercise prices equal to the fair value of the Company’s ordinary shares on the date of grant.
	The Company recognizes compensation expense for these awards on a straight-line basis over the vesting period. Share-based compensation expense is included in cost of goods sold, selling, general and administrative, and research and development expenses on the consolidated statements of operations.
	Below is a summary of the allocation of share-based compensation (in thousands):
		Year ended
		December 29,			December 30,			January 1,
		2013			2012			2012
	Cost of goods sold	$	658		$	864		$	841
	Selling, general and administrative		6,955			5,477			5,263
	Research and development		687			489			443
	Total	$	8,300		$	6,830		$	6,547
	The Company recognizes the fair value of share-based awards granted in exchange for employee services as a cost of those services. Total compensation cost included in the consolidated statements of operations for employee share-based payment arrangements was $8.0 million, $6.5 million and $6.2 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively. The increase in share-based compensation in 2013 was due to a change in the estimated forfeiture rate applied to unvested awards that resulted in $1.6 million of additional expense. The amount of expense related to non-employee options was $0.3 million, $0.3 million and $0.3 million for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively. Additionally, $0.4 million and $0.3 million of these share-based compensation costs were included in inventory as a capitalized cost as of December 29, 2013 and December 30, 2012, respectively.
	Stock Option Awards
	The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of estimates, including the expected life of stock options, expected stock price volatility, the risk-free interest rate and the expected dividend yield. The Company calculates the expected life of stock options using the SEC’s allowed short-cut method due to the relatively recent initial public offering and a lack of historical data. The expected stock price volatility assumption was estimated based upon historical volatility of the common stock of a group of the Company’s peers that are publicly traded. The risk-free interest rate was determined using U.S. Treasury rates with terms consistent with the expected life of the stock options. Expected dividend yield is not considered, as the Company has never paid dividends and currently has no plans of doing so during the term of the options. The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data when available to estimate pre-vesting option forfeitures, and records share-based compensation expense only for those awards that are expected to vest. The weighted-average fair value of the Company’s options granted to employees was $8.95, $8.55 and $12.06 per share, in 2013, 2012 and 2011, respectively. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:
		Years ended
		December 29,			January 1,			January 2,
		2013			2012			2011
	Risk-free interest rate		1.7	%		0.9	%		2.1	%
	Expected life in years		6.1			6.1			6.1
	Expected volatility		46.6	%		48.1	%		48.6	%
	Expected dividend yield		0	%		0	%		0	%
	As of December 29, 2013, the Company had $8.2 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted to employees under the 2010 Plan and the Company’s prior stock option plan. That cost is expected to be recognized over a weighted-average service period of 1.5 years. Shares reserved for future compensation grants were 2.1 million and 2.5 million at December 29, 2013 and December 30, 2012, respectively. Per share exercise prices for options outstanding at December 29, 2013 and December 30, 2012, ranged from $13.39 to $27.31.
	A summary of the Company’s employee stock option activity is as follows:
		Ordinary			Weighted-Average			Weighted-Average			Aggregate
		Shares			Per Share			Remaining			Intrinsic
		(In Thousands)			Exercise Price			Contractual Life			Value (in
								(In Years)			Millions)
	Outstanding at January 2, 2011		3,532			17.02			7.4			19.4
	Granted		647			24.76
	Exercised		(210	)		15.02
	Forfeited or expired		(73	)		20.96
	Outstanding at January 1, 2012		3,896			18.32			6.9			(3.8	)
	Granted		626			18.45
	Exercised		(426	)		16.56
	Forfeited or expired		(314	)		22.33
	Outstanding at December 30, 2012		3,782			18.23			6.4			(7.3	)
	Granted		643			19.32
	Exercised		(1,454	)		14.38
	Forfeited or expired		(543	)		22.51
	Outstanding at December 29, 2013		2,428			19.89			7.5			(3.9	)
	Exercisable at period end		1,236			20.03			6.2			(2.1	)
	The Company did not grant options to purchase ordinary shares to non-employees in the years ended December 29, 2013 and December 30, 2012. During the year ended January 1, 2012, the Company granted options to purchase 74,667 ordinary shares to non-employees in exchange for consulting services. The options granted during the year ended January 1, 2012 had a weighted-average exercise price of $19.39 per share and a weighted average grant date fair value of $9.74 per share. Related to the non-employee options, 177,013 of these options were exercisable at December 29, 2013, while 26,007 of these options were exercised in 2013 and 6,180 were forfeited. These options have vesting periods of either two or four years and expire 10 years after the grant date. The measurement date for options granted to non-employees is often after the grant date, which often requires updates to the estimate of fair value until the services are performed.
	Total stock option-related compensation expense recognized in the consolidated statements of operations, including employees and non-employees, was approximately $5.3 million, $5.0 million and $5.8 million for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	Restricted Stock Units Awards
	The Company began to grant RSUs in 2011 under the 2010 Plan. Vesting of these awards typically occurs over a four-year period and the grant date fair value of the awards is recognized as expense over the vesting period. Total compensation expense recognized in the consolidated statements of operations related to RSUs was $3.0 million, $1.8 million and $0.7 million for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.
	A summary of the Company’s activity related to RSUs is as follows:
		Shares			Weighted-Average
		(In Thousands)			Grant Date Fair
					Value Per Share
	Outstanding at January 2, 2011		—			—
	Granted		221			25.06
	Vested		(7	)		23.61
	Cancelled		(7	)		25.52
	Outstanding at January 1, 2012		207			25.1
	Granted		305			18.51
	Vested		(55	)		20.21
	Cancelled		(35	)		24.01
	Outstanding at December 30, 2012		422			20.57
	Granted		323			19.25
	Vested		(97	)		16.4
	Cancelled		(75	)		22.03
	Outstanding at December 29, 2013		573			19.54

Other_NonOperating_Income

Other Non-Operating Income	12 Months Ended
	Dec. 29, 2013
Other Income And Expenses [Abstract]	'
Other Non-Operating Income	'
	17. Other Non-Operating Income
	During the year ended December 29, 2013, the Company recognized an immaterial amount in other non-operating income. During the year ended December 30, 2012, the Company recognized $0.1 million in other non-operating income. During the year ended January 1, 2012, the Company recognized $1.3 million in non-operating income, which included a $1.0 million gain on settlement of a contingent liability and a $0.3 million gain related to the sale of certain non-operating real estate in France.

Special_Charges

Special Charges	12 Months Ended
	Dec. 29, 2013
Text Block [Abstract]	'
Special Charges	'
	18. Special Charges
	Special charges are recorded as a separate line item within operating expenses on the consolidated statement of operations and primarily include operating expenses directly related to business combinations and related integration activities, restructuring initiatives (including the facilities consolidation initiative), management exit costs and certain other items that are typically infrequent in nature and that affect the comparability and trend of operating results. The table below summarizes amounts included in special charges for the related periods:
		Year ended
		December 29,			December 30,		January 1,
		2013			2012		2012
	Facilities consolidation charges	$	—		$	6,357	$	—
	Acquisition, integration and distributor transition costs		7,143			4,920		—
	OrthoHelix restructuring charges		521			—		—
	Reduction in contingent consideration liability		(5,140	)		—		—
	Legal settlements		1,214			—		—
	Italy bad debt expense		—			2,001		—
	Management exit costs		—			1,229		632
	Intangible asset impairments		—			4,737		—
	Other		—			—		260
	Total	$	3,738		$	19,244	$	892
	Included in special charges for the year ended December 29, 2013 were $7.1 million of expenses related to acquisition and integration activities of OrthoHelix, U.S. distributor transitions, and the Company’s acquisitions of certain assets of its distributors in Canada, the United Kingdom and Australia; $5.1 million of gain recognized on the reversal of a contingent consideration liability for OrthoHelix due to updated revenue estimates; $1.2 million of expenses related to a certain legal settlement; and $0.5 million of OrthoHelix restructuring costs.
	Included in special charges for the year ended December 30, 2012 were $6.4 million of restructuring costs related to the Company’s facilities consolidation initiative. See below for further details on this initiative. Also included in special charges were intangible impairments of $4.7 million as the Company made certain strategic decisions related to previously acquired intangibles which was determined to be impaired as a result of the acquisition of OrthoHelix; acquisition and integration costs of $3.5 million which included costs related to the Company’s acquisition of OrthoHelix and the Company’s exclusive distributor in Belgium and Luxembourg; $2.0 million of bad debt expense related to certain uncollectible accounts and worsening economic conditions in Italy; distribution channel change costs of $1.4 million which included termination costs related to certain strategic business decisions made related to the Company’s U.S. and international distribution channels; and management exit costs of $1.2 million which included severance related to the Company’s former Chief Executive Officer and Global Chief Financial Officer.
	Included in special charges on the consolidated statement of operations for the year ended January 1, 2012 are $0.6 million in management termination costs and $0.3 million of charges related to the closure of the Company’s Beverly, Massachusetts facility.
	OrthoHelix Restructuring Initiative
	In December 2013, as part of the on-going integration of OrthoHelix, the Company announced the move and consolidation of various business operations from Medina, Ohio to Bloomington, Minnesota including customer service, quality, supply chain and finance functions. Charges incurred in connection with the initiative during the year ended December 29, 2013 were $0.4 million and related to termination benefits including severance and retention and $0.1 million of impairment charges for fixed assets, all of which were recorded in special charges in the consolidated statement of operations. The Company estimated it will incur $2.0 to $2.5 million in total charges related to the initiative, substantially all of which will be recorded and paid in 2014.
	Included in accrued liabilities on the consolidated balance sheet as of December 29, 2013 is an accrual related to the OrthoHelix restructuring initiative. Activity in the restructuring accrual is presented in the following table (in thousands):
	OrthoHelix restructuring accrual balance as of December 30, 2012	$	—
	Charges:
	Employee termination benefits		381
	Moving, professional fees and other initiative-related expenses		—
	Total charges		381
	Payments:
	Employee termination benefits		—
	Moving, professional fees and other initiative-related expenses		—
	Total payments		—
	OrthoHelix restructuring initiative accrual balance as of December 29, 2013	$	381
	Facilities Consolidation Initiative
	On April 13, 2012, the Company announced a facilities consolidation initiative, stating that it planned to consolidate several of its facilities to drive operational productivity. Under the initiative, the Company consolidated its Dunmanway, Ireland manufacturing facility into its Macroom, Ireland manufacturing facility in the second quarter of 2012 and, in the third quarter of 2012, the Company consolidated its St. Ismier, France manufacturing facility into its Montbonnot, France manufacturing facility. In addition, the Company leased a new facility in Bloomington, Minnesota to use as its U.S. business headquarters and consolidated its Minneapolis-based marketing, training, regulatory, supply chain, and corporate functions with its Stafford, Texas-based distribution operations. This initiative was completed in the fourth quarter of 2012.
	Charges incurred in connection with the facilities consolidation initiatives were recorded in the year ended December 30, 2012 and are presented in the following table (in thousands). All of the following amounts were recognized within special charges in the Company’s consolidated statements of operations.
		Fiscal Year Ended
		December 30, 2012
	Employee termination benefits	$	1,180
	Impairment charges related to fixed assets		872
	Moving, professional fees and other initiative-related expenses		4,305
	Total facilities consolidation expenses	$	6,357
	The $1.2 million of employee termination benefits includes severance and retention related to approximately 65 employees impacted by the facilities consolidation initiative in the United States. The $0.9 million of impairment charges related to fixed assets are a result of closing the impacted facilities in the United States, France and Ireland. The $4.3 million of moving, professional fees and other initiative-related expenses include moving and transportation expenses, lease termination costs, professional fees and other expenses that were incurred to execute the facilities consolidation initiative.
	Included in accrued liabilities on the consolidated balance sheet as of December 29, 2013 and December 30, 2012 is an accrual related to the facilities consolidation initiative. Activity in the facilities consolidation accrual is presented in the following table (in thousands):
	Facility consolidation accrual balance as of January 2, 2012	$	—
	Charges:
	Employee termination benefits		1,180
	Moving, professional fees and other initiative-related expenses		4,305
	Total charges		5,485
	Payments:
	Employee termination benefits		(620	)
	Moving, professional fees and other initiative-related expenses		(4,191	)
	Total payments		(4,811	)
	Facilities consolidation accrual balance as of December 30, 2012	$	674
	Payments:
	Employee termination benefits		(475	)
	Moving, professional fees and other initiative-related expenses		(107	)
	Total payments		(582	)
	Facilities consolidation accrual balance as of December 29, 2013	$	92

Litigation

Litigation	12 Months Ended
	Dec. 29, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Litigation	'
	19. Litigation
	From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business. These actions and proceedings may relate to, among other things, product liability, intellectual property, distributor, commercial and other matters. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, where the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that material loss may be have been incurred. In the opinion of management, as of December 29, 2013, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company’s consolidated results of operations, financial position or cash flows.

Selected_Quarterly_Information

Selected Quarterly Information (unaudited)	12 Months Ended
	Dec. 29, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Selected Quarterly Information (unaudited)	'
	20. Selected Quarterly Information (unaudited):
	The following table presents a summary of the Company’s unaudited quarterly operating results for each of the four quarters in 2013 and 2012, respectively (in thousands). This information was derived from unaudited interim financial statements that, in the opinion of management, have been prepared on a basis consistent with the financial statements contained elsewhere in this report and include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of such information when read in conjunction with the Company’s audited financial statements and related notes. The operating results for any quarter are not necessarily indicative of results for any future period.
		Year ended December 29, 2013
		Fourth			Third			Second			First
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share data)
	Revenue	$	83,392		$	66,747		$	78,135		$	82,685
	Cost of goods sold		21,267			18,972			22,309			23,624
	Gross profit		62,125			47,775			55,826			59,061
	Operating expenses:
	Selling, general and administrative		56,451			46,797			51,467			52,136
	Research and development		5,997			4,665			5,543			6,182
	Amortization of intangible assets		4,288			3,976			3,784			3,837
	Special charges		2,729			(3,918	)		3,408			1,519
	Total operating expenses		69,465			51,520			64,202			63,674
	Operating loss		(7,340	)		(3,745	)		(8,376	)		(4,613	)
	Consolidated net loss		(10,699	)		(6,292	)		(12,537	)		(6,898	)
	Net loss per share:
	basic and diluted	$	(0.22	)	$	(0.13	)	$	(0.28	)	$	(0.17	)
		Year ended December 30, 2012
		Fourth			Third			Second			First
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share data)
	Revenue	$	79,033		$	58,015		$	66,014		$	74,458
	Cost of goods sold		26,974			15,730			18,098			21,116
	Gross profit		52,059			42,285			47,916			53,342
	Operating expenses:
	Selling, general and administrative		46,290			38,524			41,795			43,838
	Research and development		6,195			5,260			5,446			5,623
	Amortization of intangible assets		3,708			2,730			2,636			2,647
	Special charges		9,831			6,503			2,910			—
	Total operating expenses		66,024			53,017			52,787			52,108
	Operating loss		(13,965	)		(10,732	)		(4,871	)		1,234
	Consolidated net loss		(4,803	)		(11,681	)		(5,084	)		(176	)
	Net loss per share:
	basic and diluted	$	(0.12	)	$	(0.29	)	$	(0.13	)	$	(0.00	)
	For the year ended December 29, 2013, the first, second, third and fourth quarters included net charges of $1.5 million, $3.4 million, $(3.9) million and $2.7 million, respectively, related to acquisition, integration and distribution channel transition charges, certain legal settlements, the partial reversal of a contingent consideration liability incurred in the acquisition of OrthoHelix and certain other items, all of which were recorded in special charges within operating expenses. The first, second, third and fourth quarters also included acquired inventory fair value adjustments of $1.8 million, $1.9 million, $1.8 million and $0.5 million, respectively, which were included in cost of goods sold.
	For the year ended December 30, 2012, the second, third and fourth quarter included charges of $1.1 million, $2.9 million and $2.5 million, respectively, related to the Company’s facilities consolidation initiative, acquisition and integration costs, intangible impairments, and certain other items, all of which were recorded in special charges within operating expenses. In addition, the fourth quarter included $2.9 million in inventory product rationalization charges and $1.6 million in acquired inventory fair value adjustments, both of which were recorded in cost of goods sold. The fourth quarter also included a $10.7 million tax benefit due to the reversal of valuation allowance from the acquisition of OrthoHelix.

Schedule_IIValuation_and_Quali

Schedule II-Valuation and Qualifying Accounts	12 Months Ended
	Dec. 29, 2013
Valuation And Qualifying Accounts [Abstract]	'
Schedule II-Valuation and Qualifying Accounts	'
	Tornier N.V.
	Schedule II-Valuation and Qualifying Accounts
	(In thousands)
						Additions
			Balance at			Charged to			Deductions					Balance at
			beginning			costs &								end
	Description		of period			expenses			Describe(a)		Describe(b)			of period
	Allowance for Doubtful Accounts:
	Year ended December 29, 2013		$	(4,846	)		(1,220	)		1,208		(222	)	$	(5,080	)
	Year ended December 30, 2012		$	(2,486	)		(2,355	)		87		(92	)	$	(4,846	)
	Year ended January 1, 2012		$	(2,519	)	$	(775	)	$	755	$	53		$	(2,486	)
	(a)	Uncollectible amounts written off, net of recoveries.
	(b)	Effect of changes in foreign exchange rates.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 29, 2013

Accounting Policies [Abstract]

'

Consolidation

'

Consolidation

The consolidated financial statements include the accounts of the Company and all of its wholly and majority owned subsidiaries. In consolidation, all material intercompany accounts and transactions are eliminated.

Use of Estimates

'

Use of Estimates

The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (U.S. GAAP) and include amounts that are based on management’s best estimates and judgments. Actual results could differ from those estimates.

Foreign Currency Translation

'

Foreign Currency Translation

The functional currencies for the Company and all of the Company’s wholly owned subsidiaries are their local currencies. The reporting currency of the Company is the U.S. dollar. Accordingly, the consolidated financial statements of the Company and its international subsidiaries are translated into U.S. dollars using current exchange rates for the consolidated balance sheets and average exchange rates for the consolidated statements of operations and cash flows. Unrealized translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders’ equity. When a transaction is denominated in a currency other than the subsidiary’s functional currency, the Company recognizes a transaction gain or loss in net earnings. Foreign currency transaction (losses) gains included in net earnings were $(1.8) million, $(0.5) million and $0.2 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.

Revenue Recognition

'

Revenue Recognition

The Company derives revenue from the sale of medical devices that are used by orthopaedic and general surgeons who treat diseases and disorders of extremity joints, including the shoulder, elbow, wrist, hand, ankle and foot, and large joints, including the hip and knee. Revenue is generated from sales to two types of customers: healthcare institutions and stocking distributors, with sales to healthcare institutions representing a majority of the Company’s revenue. Revenue from sales to healthcare institutions is recognized at the time of surgical implantation. Revenue from sales to stocking distributors is recorded at the time the product is shipped to the distributor. These stocking distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at the time of shipment. Stocking distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. In certain circumstances, the Company may accept sales returns from distributors and in certain situations in which the right of return exists, the Company estimates a reserve for sales returns and recognizes the reserve as a reduction of revenue. The Company bases its estimate for sales returns on historical sales and product return information including historical experience and trend information. The Company’s reserve for sales returns has historically been immaterial.

Shipping and Handling

'

Shipping and Handling

Amounts billed to customers for shipping and handling of products are reflected in revenue and are not considered significant. Costs related to shipping and handling of products are expensed as incurred, are included in selling, general and administrative expense, and were $5.7 million, $5.1 million and $5.2 million for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.

Cash and Cash Equivalents

'

Cash and Cash Equivalents

Cash equivalents are highly liquid investments with an original maturity of three months or less. The carrying amount reported in the consolidated balance sheets for cash and cash equivalents is cost, which approximates fair value.

Accounts Receivable

'

Accounts Receivable

Accounts receivable consist of customer trade receivables. The Company maintains an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. The Company makes estimates regarding the future ability of its customers to make required payments based on historical credit experience, delinquency and expected future trends. The majority of the Company’s receivables are from healthcare institutions, many of which are government-funded. The Company’s allowance for doubtful accounts was $5.1 million and $4.8 million at December 29, 2013 and December 30, 2012, respectively. Accounts receivable are written off when it is determined that the accounts are uncollectible, typically upon customer bankruptcy or the customer’s non-response to continued collection efforts.

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. The allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. As of December 29, 2013, there were no customers that accounted for more than 10% of accounts receivable.

Royalties

'

Royalties

The Company pays royalties to certain individuals and companies that have developed and retain the legal rights to the technology or have assisted the Company in the development of technology or new products. These royalties are based on sales and are reflected as selling, general and administrative expenses in the consolidated statements of operations.

Inventories

'

Inventories

Inventories, net of reserves for obsolete and slow-moving goods, are stated at the lower of cost or market value. Cost is determined on a first-in, first-out (FIFO) basis. Costs included in the value of inventory that Tornier manufactures include the material costs, direct labor costs and manufacturing and distribution overhead costs. Inventories consist of raw materials, work-in-process and finished goods. Finished goods inventories are held primarily in the United States, several countries in Europe, Canada, Japan and Australia and consist primarily of joint implants and related orthopaedic products. Inventory balances, net of reserves, consist of the following (in thousands):

December 29,

December 30,

2013

2012

Raw materials

$

6,840

$

5,696

Work in process

9,171

4,933

Finished goods

71,000

76,068

Total

$

87,011

$

86,697

The Company regularly reviews inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incurs charges to write down inventories to their net realizable value. The Company’s review of inventory for excess and obsolete quantities is based primarily on the estimated forecast of future product demand, production requirements, and introduction of new products. The Company recognized $8.4 million, $8.2 million and $5.0 million of expense for excess and obsolete inventory in cost of goods sold during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively. The increase in excess and obsolete charges in 2012 included a $3.0 million charge related to rationalization of products associated with the integration of OrthoHelix into Tornier. Additionally, the Company had $47.8 million and $44.5 million in inventory held on consignment with third-party distributors and healthcare facilities, among others, at December 29, 2013 and December 30, 2012, respectively.

Property, Plant and Equipment

'

Property, Plant and Equipment

Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on estimated useful lives of five to thirty-nine years for buildings and improvements and two to eight years for machinery and equipment. The cost of maintenance and repairs is expensed as incurred. The Company reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset’s carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value.

For the year ended December 29, 2013, the Company recorded $0.1 million in impairment related to the fixed assets located in Medina, Ohio that the Company is abandoning as part of its OrthoHelix restructuring plan. As a result of the Company’s facilities consolidation initiative in 2012, the Company recorded several fixed asset impairments related to the Company’s facilities in St. Ismier, France, Dunmanway, Ireland, and Stafford, Texas in the aggregate amount of $0.9 million for the year ended December 30, 2012.

Software Development Costs

'

Software Development Costs

The Company capitalizes certain computer software and software development costs incurred in connection with developing or obtaining computer software for internal use when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs generally include external direct costs of materials and services utilized in developing or obtaining computer software and compensation and related benefits for employees who are directly associated with the software project. Capitalized software costs are included in property, plant and equipment on the Company’s consolidated balance sheet and amortized on a straight-line basis when the software is ready for its intended use over the estimated useful lives of the software, which approximate three to ten years.

Instruments

'

Instruments

Instruments are surgical tools used by orthopaedic and general surgeons during joint replacement and other surgical procedures to facilitate the implantation of the Company’s products. Instruments are recognized as long-lived assets. Instruments and instrument parts that have not been placed in service are carried at cost, and are included as instruments in progress within instruments, net on the consolidated balance sheets. Once placed in service, instruments are carried at cost, less accumulated depreciation. Depreciation is computed using the straight-line method based on average estimated useful lives. Estimated useful lives are determined principally in reference to associated product life cycles, and average five years. Instrument parts used to maintain the functionality of instruments but do not extend the life of the instruments are expensed as they are consumed and recorded as part of selling, general and administrative expense. The Company reviews instruments for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the assets are less than the assets’ carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. No impairment losses were recognized during the years ended December 29, 2013 and January 1, 2012. The Company recorded impairment charges of $1.0 million during the year ended December 30, 2012 related to instrument sets and components that were impaired as a result of revisions to existing product lines. Instruments included in long-term assets on the consolidated balance sheets are as follows (in thousands):

December 29,

December 30,

2013

2012

Instruments

$

99,754

$

85,869

Instruments in progress

23,990

18,171

Accumulated depreciation

(60,689

)

(52,646

)

Instruments, net

$

63,055

$

51,394

The Company provides instruments to surgeons for use in surgeries and retains title to the instruments. As instruments are used as tools to assist surgeons, depreciation of instruments is recognized as a selling, general and administrative expense. Instrument depreciation expense was $13.9 million, $12.4 million and $11.0 million during the years ended December 29, 2013, December 30, 2012 and January 1, 2012, respectively.

Business Combinations

'

Business Combinations

For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, generally at their fair values starting in the period when the acquisition is completed. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred.

Goodwill

'

Goodwill

Goodwill is recognized as the excess of the purchase price over the fair value of net assets of businesses acquired. Goodwill is not amortized, but is subject to impairment tests. Based on the Company’s single business approach to decision-making, planning and resource allocation, management has determined that the Company has one reporting unit for the purpose of evaluating goodwill for impairment. The Company performs its annual goodwill impairment test as of the first day of the fourth quarter of its fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. Impairment tests are done by qualitatively assessing the likeliness for impairment and then, if necessary, comparing the reporting unit’s fair value to its carrying amount to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill. The fair value of the reporting unit and the implied fair value of goodwill are determined based on widely accepted valuation techniques. No goodwill impairment losses were recorded during the years ended December 29, 2013, December 30, 2012 and January 1, 2012 as the fair value of the reporting unit significantly exceeded its carrying value.

Intangible Assets

'

Intangible Assets

Intangible assets with an indefinite life, including certain trademarks and trade names, are not amortized, but are tested for impairment annually or whenever events or circumstances indicate that the carrying amount may not be recoverable. Any amount of impairment loss to be recorded would be determined based upon the excess of the asset’s carrying value over its fair value. No impairment losses on indefinite life intangibles were recorded during the years ended December 29, 2013, December 30, 2012 and January 1, 2012. The useful lives of these assets are also assessed annually to determine whether events and circumstances continue to support an indefinite life.

Intangible assets with a finite life, including developed technology, customer relationships, and patents and licenses, are amortized on a straight-line basis over their estimated useful lives, ranging from one to twenty years. Costs incurred to extend or renew license arrangements are capitalized as incurred and amortized over the shorter of the life of the extension or renewal, or the remaining useful life of the underlying product being licensed. Intangible assets with a finite life are tested for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset’s carrying amount and would be measured as the amount by which the carrying amount of an asset exceeds its fair value. For the year ended December 29, 2013, the Company recognized an impairment charge of $0.1 million related to license intangibles that are no longer being used. For the year ended December 30, 2012, the Company recognized an impairment charge of $4.7 million related to developed technology and customer relationship intangibles whose fair values were negatively impacted by the acquisition of OrthoHelix. The fair value of the intangibles was determined using a discounted cash flow analysis. For the year ended January 1, 2012, the Company recognized an impairment charge of $0.2 million related to developed technology from acquired entities that was no longer being used. For the years ended December 29, 2013 and January 1, 2012, intangible asset impairments are included in amortization of intangible assets in the consolidated statements of operations. For the year ended December 30, 2012, intangible asset impairments are included in special charges on the consolidated statement of operations as they related directly to the acquisition and integration of OrthoHelix.

Derivative Financial Instruments

'

Derivative Financial Instruments

All of the Company’s derivative instruments are economic hedges and are recorded in the accompanying consolidated balance sheets as either an asset or liability and are measured at fair value. The changes in the derivative’s fair value are recognized in earnings as a component of foreign currency transaction gain (loss) in the period in which the change occurred.

Research and Development

'

Research and Development

All research and development costs are expensed as incurred.

Income Taxes

'

Income Taxes

Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances for deferred tax assets are recognized if it is more likely than not that some component or all of the benefits of deferred tax assets will not be realized.

The Company accrues interest and penalties related to unrecognized tax benefits in the Company’s provision for income taxes. In the fiscal years ended December 29, 2013 and December 30, 2012, accrued interest and penalties were $0.3 million and $0.2 million, respectively.

Other Comprehensive Income (Loss)

'

Other Comprehensive Income (Loss)

Other comprehensive income (loss) refers to revenues, expenses, gains, and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings, as these amounts are recorded directly as an adjustment to shareholders’ equity. Other comprehensive income (loss) is comprised mainly of foreign currency translation adjustments and unrealized gains (losses) on retirement plans. These amounts are presented in the consolidated statements of comprehensive loss.

Share-Based Compensation

'

Share-Based Compensation

The Company accounts for share-based compensation in accordance with Accounting Standards Codification (ASC) Topic 718, Compensation – Stock Compensation, which requires share-based compensation cost to be measured at the grant date based on the fair value of the award and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. The determination of the fair value of share-based payment awards, such as options, is made on the date of grant using an option-pricing model is affected by the Company’s share price, as well as assumptions regarding a number of complex and subjective variables, which include the expected life of the award, the expected share price volatility over the expected life of the award, expected dividend yield and risk-free interest rate.

New Accounting Pronouncements

'

New Accounting Pronouncements

In June 2013, the FASB issued Accounting Standards Update (ASU) 2013-11, Income Taxes (ASC Topic 740), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The ASU requires entities to present unrecognized tax benefits as a decrease in a net operating loss, similar to tax loss or tax credit carryforward if certain criteria are met. The standard clarifies presentation requirements for unrecognized tax benefits but will not alter the way in which entities assess deferred tax assets for realizability. The guidance is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013. The Company will adopt this guidance beginning in the first quarter of 2014. The impact of adoption is not expected to be material.

In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (ASC Topic 830), Parent’s Accounting for the Cumulative Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. The ASU requires entities to release cumulative translation adjustments to earnings when an entity ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity and the sale or transfer results in the complete or substantially complete liquidation of the foreign entity. The ASU is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013 and is to be applied prospectively. The Company will adopt this guidance in the first quarter of 2014 and will affect the accounting for any future liquidation of foreign subsidiaries.

In February 2013, the FASB issued ASU 2013-04, Liabilities (ASC Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. The ASU requires an entity that is jointly and severally liable to measure the obligation as the sum of the amount the entity has agreed with co-obligors to pay and any additional amount it expects to pay on behalf of one or more co-obligors. The amendment is effective for the fiscal year, and interim periods with that fiscal year, beginning after December 15, 2013 and should be applied retrospectively. The Company will adopt this guidance in the first quarter of 2014. The impact of adoption is expected to be immaterial.

Fair Value of Financial Instruments

'

Fair Value of Financial Instruments

The Company measures certain assets and liabilities at fair value on a recurring or non-recurring basis based on the application of ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. This requires fair value measurements to be classified and disclosed in one of the following three categories:

Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.

Level 2—Assets and liabilities determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3—Assets and liabilities that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the asset or liability. The prices are determined using significant unobservable inputs or valuation techniques.

A summary of the financial assets and liabilities that are measured at fair value on a recurring basis at December 29, 2013 and December 30, 2012 are as follows:

December 29, 2013

Quoted Prices in

Significant Other

Significant

Active Markets

Observable Inputs

Unobservable

(Level 1)

(Level 2)

Inputs (Level 3)

Cash and cash equivalents

$

56,784

$

56,784

$

—

$

—

Contingent consideration

(12,956

)

—

—

(12,956

)

Derivative asset

238

—

238

—

Total, net

$

44,066

$

56,784

$

238

$

(12,956

)

December 30, 2012

Quoted Prices in

Significant Other

Significant

Active Markets

Observable Inputs

Unobservable

(Level 1)

(Level 2)

Inputs (Level 3)

Cash and cash equivalents

$

31,108

$

31,108

$

—

$

—

Contingent consideration

(15,265

)

—

—

(15,265

)

Derivative asset

274

—

274

—

Total, net

$

16,117

$

31,108

$

274

$

(15,265

)

As of December 29, 2013 and December 30, 2012 the Company had a derivative asset with a fair value of $0.2 million and $0.3 million, respectively, with recurring Level 2 fair value measurements. The derivatives are foreign exchange forward contracts and their fair values are based on pricing for similar recently executed transactions. The amount of gain (loss) recognized in foreign exchange loss for the year ended December 29, 2013 and December 30, 2012 related to this derivative is approximately $0.4 million and $0.3 million, respectively. Included in Level 3 fair value measurements as of December 29, 2013 is a $10.4 million contingent consideration liability related to potential earnout payments for the acquisition of OrthoHelix that was completed in October 2012, a $1.9 million contingent consideration liability related to earn-out payments for distributor acquisitions in the United States that occurred throughout 2013, a $0.5 million contingent consideration liability related to potential earnout payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg that was completed in May 2012 and a $0.2 million contingent consideration liability related to potential earnout payments related to the acquisition of a distributor in Australia. Contingent consideration liabilities are carried at fair value and included in contingent consideration (short term and long term) on the consolidated balance sheet. The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates and a discount rate, which are considered significant unobservable inputs as of December 29, 2013. The revenue estimates were based on current management expectations for these businesses and the discount rate used was between 8-11% and was based on the Company’s estimated weighted average cost of capital for each transaction. To the extent that these assumptions were to change, the fair value of the contingent consideration liabilities could change significantly. Included in interest expense on the consolidated statement of operations for the year ended December 29, 2013 is $1.1 million related to the accretion of the contingent consideration. There were no transfers between levels during the year ended December 29, 2013.

Included in Level 3 fair value measurements as of December 30, 2012 is a $14.5 million contingent consideration liability related to potential earn-out payments for the acquisition of OrthoHelix and a $0.7 million contingent consideration liability related to potential earn-out payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg. The contingent consideration liabilities are carried at fair value, which is determined based on a discounted cash flow analysis that included revenue estimates and a discount rate, which are considered significant unobservable inputs as of December 30, 2012. The revenue estimates were based on then current management expectations for these businesses and the discount rate used as of December 30, 2012 was 8% and was based on the Company’s estimated weighted average cost of capital. Included in interest expense on the consolidated statement of operations for the year ended December 30, 2012 is $0.3 million related to the accretion of the contingent consideration. There were no transfers between levels during the year ended December 30, 2012.

A rollforward of the level 3 contingent liability for the year ended December 29, 2013 is as follows (in thousands):

Contingent consideration liability at December 30, 2012

$

15,265

Additions

3,329

Fair value adjustments

(5,140

)

Settlements

(1,640

)

Interest accretion

1,132

Foreign currency translation

10

Contingent consideration at December 29, 2013

12,956

The Company also has assets and liabilities that are measured at fair value on a non-recurring basis. The Company reviews the carrying amount of its long-lived assets other than goodwill for potential impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. During the year ended December 30, 2012, the Company recognized an intangible impairment of $4.7 million. The impairment was determined using a discounted cash flow analysis. Key inputs into the analysis included estimated future revenues and expenses and a discount rate. The discount rate of 8% was based on the Company’s weighted average cost of capital. These inputs are considered to be significant unobservable inputs and are considered Level 3 fair value measurements. No intangible impairments were recorded for the year ended December 29, 2013.

During the year ended December 30, 2012, the Company initiated and completed a facilities consolidation initiative that included the closure and consolidation of certain facilities in France, Ireland and the United States, which resulted in the recognition of a $0.9 million impairment charge to write down certain fixed assets to their estimated fair values. The fair value calculations were performed using a cost-to-sell analysis and are considered Level 2 fair value measurements as the key inputs into the calculations included estimated market values of the facilities, which are considered indirect observable inputs. In addition, the Company recorded $0.7 million of lease termination costs for the year ended December 30, 2012 related to the facilities consolidation initiative. The termination costs were determined using a discounted cash flow analysis that included a discount rate assumption, which is based on the credit adjusted risk free interest rate input, and an assumption related to the timing and amount of sublease income. The timing of the sublease income is a significant unobservable input and thus is considered a Level 3 fair value measurement. As of December 29, 2013, the value of this liability was approximately $0.4 million.

As of December 29, 2013 and December 30, 2012, the Company had short-term and long-term debt of $69.1 million and $120.1 million, respectively, the vast majority of which was variable rate debt. The fair value of the Company’s debt obligations approximates carrying value as a result of its variable rate term and would be considered a Level 2 measurement.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 29, 2013
Accounting Policies [Abstract]	'
Inventory Balances Net of Reserves	'
	Inventory balances, net of reserves, consist of the following (in thousands):
		December 29,			December 30,
		2013			2012
	Raw materials	$	6,840		$	5,696
	Work in process		9,171			4,933
	Finished goods		71,000			76,068
	Total	$	87,011		$	86,697
Instruments Included in Long-Term Assets	'
	Instruments included in long-term assets on the consolidated balance sheets are as follows (in thousands):
		December 29,			December 30,
		2013			2012
	Instruments	$	99,754		$	85,869
	Instruments in progress		23,990			18,171
	Accumulated depreciation		(60,689	)		(52,646	)
	Instruments, net	$	63,055		$	51,394

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 29, 2013
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities Measured at Fair Value	'
	A summary of the financial assets and liabilities that are measured at fair value on a recurring basis at December 29, 2013 and December 30, 2012 are as follows:
		December 29, 2013			Quoted Prices in		Significant Other		Significant
					Active Markets		Observable Inputs		Unobservable
					(Level 1)		(Level 2)		Inputs (Level 3)
	Cash and cash equivalents	$	56,784		$	56,784	$	—	$	—
	Contingent consideration		(12,956	)		—		—		(12,956	)
	Derivative asset		238			—		238		—
	Total, net	$	44,066		$	56,784	$	238	$	(12,956	)
		December 30, 2012			Quoted Prices in		Significant Other		Significant
					Active Markets		Observable Inputs		Unobservable
					(Level 1)		(Level 2)		Inputs (Level 3)
	Cash and cash equivalents	$	31,108		$	31,108	$	—	$	—
	Contingent consideration		(15,265	)		—		—		(15,265	)
	Derivative asset		274			—		274		—
	Total, net	$	16,117		$	31,108	$	274	$	(15,265	)
Summary of Contingent Consideration Liability	'
	A rollforward of the level 3 contingent liability for the year ended December 29, 2013 is as follows (in thousands):
	Contingent consideration liability at December 30, 2012	$	15,265
	Additions		3,329
	Fair value adjustments		(5,140	)
	Settlements		(1,640	)
	Interest accretion		1,132
	Foreign currency translation		10
	Contingent consideration at December 29, 2013		12,956

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 29, 2013
Business Combinations [Abstract]	'
Schedule of Preliminary Allocation of Purchase Price	'
	The following represents the allocation of the purchase price:
		Purchase Price
		Allocation
		(In Thousands)
	Goodwill	$	105,904
	Other intangible assets		40,600
	Tangible assets acquired and liabilities assumed:
	Accounts receivable		4,330
	Inventory		12,033
	Other assets		776
	Instruments, net		4,475
	Accounts payable and accrued liabilities		(3,606	)
	Deferred income taxes		(11,900	)
	Other long-term debt		(16	)
	Total purchase price	$	152,596
Summary of Identifiable Intangible Assets and their Estimated Useful Lives at Acquisition	'
	The following table represents components of these identifiable intangible assets and their estimated useful lives at the acquisition date:
		Fair Value			Estimated Useful
		(In Thousands)			Life
					(In Years)
	Developed technology	$	35,500			10
	In-process research and development		3,500			N/A
	Trademarks and trade names		1,500			3
	Non-compete agreements		100			3
	Total identifiable intangible assets	$	40,600
Pro forma Results of Operations	'
	Pro forma results of operations (unaudited) of the Company for the years ended December 30, 2012 and January 1, 2012, as if the acquisition had occurred on January 3, 2011, are as follows:
		Year Ended			Year Ended
		December 30,			January 1,
		2012			2012
	Revenue	$	298,051		$	283,370
	Net loss		(31,390	)		(43,155	)
	Basic and diluted net loss per share	$	(0.75	)	$	(1.07	)

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 29, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment Balances	'
	Property, plant and equipment balances are as follows (in thousands):
		December 29,			December 30,
		2013			2012
	Land	$	1,886		$	1,830
	Building and improvements		14,255			12,908
	Machinery and equipment		31,192			25,767
	Furniture, fixtures and office equipment		29,371			26,541
	Software		5,511			4,729
	Construction in progress		5,628			2,148
			87,843			73,923
	Accumulated depreciation		(44,349	)		(36,772	)
	Property, plant and equipment, net	$	43,494		$	37,151

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 29, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Changes in Carrying Amount of Goodwill	'
	The following table summarizes the changes in the carrying amount of goodwill for the years ended December 29, 2013 and December 30, 2012 (in thousands):
	Balance at January 1, 2012	$	130,544
	Contingent payment on acquisition		1,193
	Goodwill acquired in acquisitions		106,654
	Foreign currency translation		1,413
	Balance at December 30, 2012	$	239,804
	Goodwill acquired in acquisitions		8,239
	Foreign currency translation		3,497
	Balance at December 29, 2013	$	251,540
Components of Identifiable Intangible Assets	'
	The components of identifiable intangible assets are as follows (in thousands):
		Gross		Accumulated			Net Value
		Value		Amortization
	Balances at December 29, 2013
	Intangible assets subject to amortization:
	Developed technology	$	112,782	$	(44,161	)	$	68,621
	Customer relationships		61,783		(30,155	)		31,628
	Licenses		6,810		(4,004	)		2,806
	In-process research and development		400		—			400
	Other		6,624		(2,431	)		4,193
	Intangible assets not subject to amortization:
	Tradename		9,960		—			9,960
	Total	$	198,359	$	(80,751	)	$	117,608
		Gross		Accumulated			Net Value
		Value		Amortization
	Balances at December 30, 2012
	Intangible assets subject to amortization:
	Developed technology	$	108,274	$	(34,114	)	$	74,160
	Customer relationships		59,212		(24,634	)		34,578
	Licenses		5,525		(2,927	)		2,598
	In-process research and development		3,200		—			3,200
	Other		3,923		(1,357	)		2,566
	Intangible assets not subject to amortization:
	Tradename		9,492		—			9,492
	Total	$	189,626	$	(63,032	)	$	126,594
Weighted Average Amortization Periods by Major Intangible Asset Class	'
	The weighted-average amortization periods, by major intangible asset class, are as follows:
		Weighted-Average
		Amortization Period
		(In Years)
	Developed technology		12
	Customer relationships		13
	Licenses		5
	In-process research and development		—
	Other		3
Estimated Annual Amortization Expense	'
	Estimated annual amortization expense for fiscal years ending 2014 through 2018 is as follows (in thousands):
		Amortization Expense
	2014	$	16,866
	2015		16,420
	2016		14,213
	2017		13,299
	2018		12,475

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 29, 2013
Payables And Accruals [Abstract]	'
Accrued liabilities	'
	Accrued liabilities consist of the following (in thousands):
		December 29, 2013		December 30, 2012
	Accrued payroll and related expenses	$	21,499	$	16,521
	Accrued royalties		9,169		9,001
	Accrued sales and use tax		4,727		2,022
	Accrued agent commissions		4,554		5,266
	Other accrued liabilities		10,765		11,599
		$	50,714	$	44,410

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 29, 2013
Debt Disclosure [Abstract]	'
Summary of Debt	'
	A summary of long-term debt is as follows (in thousands):
		December 29,			December 30,
		2013			2012
	Lines of credit and overdraft arrangements	$	—		$	1,000
	Mortgages		4,993			3,719
	Bank term debt		61,769			113,135
	Shareholder debt		2,319			2,198
	Total debt		69,081			120,052
	Less current portion		(1,438	)		(4,595	)
	Long-term debt	$	67,643		$	115,457
Schedule of Aggregate Maturities of Debt	'
	Aggregate maturities of debt for the next five years are as follows (in thousands):
	2014	$	1,438
	2015		1,275
	2016		1,447
	2017		61,406
	2018		649
	Thereafter		2,866
Summary of Borrowings	'
	Borrowings under these facilities within the credit agreement as of December 29, 2013 and December 30, 2012 were as follows:
		December 29,			December 30,
		2013			2012
	Senior secured U.S. dollar term loan	$	64,031		$	75,925
	Senior secured Euro term loan		—			40,772
	Debt discount		(3,157	)		(5,138	)
	Total	$	60,874		$	111,559

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 29, 2013
Income Tax Disclosure [Abstract]	'
Components of Earnings (Loss) Before Taxes	'
	The components of earnings (loss) before taxes for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, consist of the following (in thousands):
		December 29,			December 30,			January 1,
		2013			2012			2012
	United States loss	$	(33,204	)	$	(19,858	)	$	(2,631	)
	Rest of the world loss		(873	)		(12,821	)		(36,249	)
	Loss before taxes	$	(34,077	)	$	(32,679	)	$	(38,880	)
Summary of Income Tax Benefit (Provision)	'
	The income tax benefit (provision) for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, consists of the following (in thousands):
		December 29,			December 30,			January 1,
		2013			2012			2012
	Current (provision) benefit:
	United States	$	(94	)	$	(150	)	$	(327	)
	Rest of the world		(3,513	)		(2,523	)		(3,140	)
	Deferred (provision) benefit		1,258			13,608			11,891
	Total income tax (provision) benefit	$	(2,349	)	$	10,935		$	8,424
Reconciliation of Effective Tax Rate	'
	A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate for the years ended December 29, 2013, December 30, 2012 and January 1, 2012, is as follows:
		December 29,			December 30,			January 1,
		2013			2012			2012
	Income tax provision at U.S. statutory rate		34	%		34	%		34	%
	Release of valuation allowance		3.3			32.8			—
	Change in valuation allowance		(38.6	)		(33.4	)		(10.1	)
	Tax benefit from disregarded entity		1.8			1.7			6.4
	State and local taxes		(4.7	)		2.6			(0.4	)
	Tax deductible IPO costs		2			1.7			—
	Other foreign taxes		(3.5	)		(3.5	)		(2.0	)
	Unrecognized interest deduction		—			—			(0.5	)
	Contingent consideration adjustment to market value		4.1			—			—
	Stock option cancellation		(8.1	)
	Impact of foreign income tax rates		2.1			(2.5	)		(6.9	)
	Non-deductible expenses		(1.1	)		(1.8	)		(0.6	)
	Other		1.8			1.9			1.7
	Total		(6.9	)%		33.5	%		21.6	%
Components of Deferred Taxes	'
	The components of deferred taxes for the years ended December 29, 2013 and December 30, 2012, consist of the following (in thousands):
		December 29,			December 30,
		2013			2012
	Deferred tax assets:
	Net operating loss and tax credit carryforwards	$	41,456		$	27,924
	Inventory		7,294			4,960
	Exchange rate changes		102			223
	Stock options		7,082			9,715
	Accruals and other provisions		6,161			5,067
	Total deferred tax assets		62,095			47,889
	Less: valuation allowance		(40,441	)		(30,011	)
	Total deferred tax assets after valuation allowance		21,654			17,878
	Deferred tax liabilities:
	Intangible assets		(33,553	)		(33,248	)
	Depreciation		(3,342	)		(2,033	)
	Total deferred tax liabilities		(36,895	)		(35,281	)
	Total net deferred tax liabilities	$	(15,241	)	$	(17,403	)
Reconciliation of Unrecognized Tax Benefits	'
	A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows (in thousands):
	Gross unrecognized tax benefits at January 1, 2012	$	5,232
	Increase for tax positions in prior years		2,282
	Decrease for tax positions in prior years		—
	Increase for tax positions in current year		306
	Foreign currency translation		89
	Gross unrecognized tax benefits at December 30, 2012	$	7,909
	Increase for tax positions in prior years		58
	Decrease for tax positions in prior years		—
	Settlements		(2,094	)
	Increase for tax positions in current year		307
	Foreign currency translation		236
	Gross unrecognized tax benefits at December 29, 2013	$	6,416

Segment_and_Geographic_Data_Ta

Segment and Geographic Data (Tables)	12 Months Ended
	Dec. 29, 2013
Segment Reporting [Abstract]	'
Summary of Revenue by Geographic Region	'
	Revenue by geographic region is as follows (in thousands):
		Year Ended
		December 29,		December 30,		January 1,
		2013		2012		2012
	Revenue by geographic region:
	United States	$	182,104	$	156,750	$	141,496
	France		58,173		52,737		55,438
	Other international		70,682		68,033		64,257
	Total	$	310,959	$	277,520	$	261,191
Summary of Revenue by Product Category	'
	Revenue by product category is as follows (in thousands):
		Year Ended
		December 29,		December 30,		January 1,
		2013		2012		2012
	Revenue by product type:
	Upper extremity joints and trauma	$	184,457	$	175,242	$	164,064
	Lower extremity joints and trauma		58,747		34,109		26,033
	Sports medicine and biologics		14,752		15,526		14,779
	Total extremities		257,956		224,877		204,876
	Large joints and other		53,003		52,643		56,315
	Total	$	310,959	$	277,520	$	261,191
Summary of Long Lived Tangible Assets Including Instruments and Property Plant and Equipment	'
	Long-lived tangible assets, including instruments and property, plant and equipment are as follows (in thousands):
		December 29,		December 30,		January 1,
		2013		2012		2012
	Long-lived assets:
	United States	$	40,032	$	31,342	$	25,221
	France		45,909		39,764		40,564
	Other international		20,608		17,439		16,915
	Total	$	106,549	$	88,545	$	82,700

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 29, 2013
Leases [Abstract]	'
Future Minimum Rental Commitments Under Non-cancelable Operating Leases	'
	Future minimum rental commitments under non-cancelable operating leases in effect as of December 29, 2013 are as follows (in thousands):
	2014	$	5,410
	2015		4,500
	2016		3,535
	2017		3,286
	2018		3,050
	Thereafter		8,362
	Total	$	28,143
Future Lease Payments Under Capital Leases	'
	Future lease payments under capital leases are as follows (in thousands):
	2014	$	461
	2015		269
	2016		114
	2017		70
	Total minimum lease payments		914
	Less amount representing interest		(67	)
	Present value of minimum lease payments		847
	Current portion		(448	)
	Long-term portion	$	399

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 29, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Allocation of Share-Based Compensation	'
	Below is a summary of the allocation of share-based compensation (in thousands):
		Year ended
		December 29,			December 30,			January 1,
		2013			2012			2012
	Cost of goods sold	$	658		$	864		$	841
	Selling, general and administrative		6,955			5,477			5,263
	Research and development		687			489			443
	Total	$	8,300		$	6,830		$	6,547
Share-Based Compensation Weighted-Average Assumptions	'
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:
		Years ended
		December 29,			January 1,			January 2,
		2013			2012			2011
	Risk-free interest rate		1.7	%		0.9	%		2.1	%
	Expected life in years		6.1			6.1			6.1
	Expected volatility		46.6	%		48.1	%		48.6	%
	Expected dividend yield		0	%		0	%		0	%
Summary of Employee Stock Option Activity	'
	A summary of the Company’s employee stock option activity is as follows:
		Ordinary			Weighted-Average			Weighted-Average			Aggregate
		Shares			Per Share			Remaining			Intrinsic
		(In Thousands)			Exercise Price			Contractual Life			Value (in
								(In Years)			Millions)
	Outstanding at January 2, 2011		3,532			17.02			7.4			19.4
	Granted		647			24.76
	Exercised		(210	)		15.02
	Forfeited or expired		(73	)		20.96
	Outstanding at January 1, 2012		3,896			18.32			6.9			(3.8	)
	Granted		626			18.45
	Exercised		(426	)		16.56
	Forfeited or expired		(314	)		22.33
	Outstanding at December 30, 2012		3,782			18.23			6.4			(7.3	)
	Granted		643			19.32
	Exercised		(1,454	)		14.38
	Forfeited or expired		(543	)		22.51
	Outstanding at December 29, 2013		2,428			19.89			7.5			(3.9	)
	Exercisable at period end		1,236			20.03			6.2			(2.1	)
Summary of Activities Related to Restricted Stock Units	'
	A summary of the Company’s activity related to RSUs is as follows:
		Shares			Weighted-Average
		(In Thousands)			Grant Date Fair
					Value Per Share
	Outstanding at January 2, 2011		—			—
	Granted		221			25.06
	Vested		(7	)		23.61
	Cancelled		(7	)		25.52
	Outstanding at January 1, 2012		207			25.1
	Granted		305			18.51
	Vested		(55	)		20.21
	Cancelled		(35	)		24.01
	Outstanding at December 30, 2012		422			20.57
	Granted		323			19.25
	Vested		(97	)		16.4
	Cancelled		(75	)		22.03
	Outstanding at December 29, 2013		573			19.54

Special_Charges_Tables

Special Charges (Tables)	12 Months Ended
	Dec. 29, 2013
Schedule of Special Charges	'
	The table below summarizes amounts included in special charges for the related periods:
		Year ended
		December 29,			December 30,		January 1,
		2013			2012		2012
	Facilities consolidation charges	$	—		$	6,357	$	—
	Acquisition, integration and distributor transition costs		7,143			4,920		—
	OrthoHelix restructuring charges		521			—		—
	Reduction in contingent consideration liability		(5,140	)		—		—
	Legal settlements		1,214			—		—
	Italy bad debt expense		—			2,001		—
	Management exit costs		—			1,229		632
	Intangible asset impairments		—			4,737		—
	Other		—			—		260
	Total	$	3,738		$	19,244	$	892
Amounts Recognized Within Special Charges Related to Restructuring	'
	All of the following amounts were recognized within special charges in the Company’s consolidated statements of operations.
		Fiscal Year Ended
		December 30, 2012
	Employee termination benefits	$	1,180
	Impairment charges related to fixed assets		872
	Moving, professional fees and other initiative-related expenses		4,305
	Total facilities consolidation expenses	$	6,357
Activity in Facilities Consolidation Accrual	'
	Activity in the facilities consolidation accrual is presented in the following table (in thousands):
	Facility consolidation accrual balance as of January 2, 2012	$	—
	Charges:
	Employee termination benefits		1,180
	Moving, professional fees and other initiative-related expenses		4,305
	Total charges		5,485
	Payments:
	Employee termination benefits		(620	)
	Moving, professional fees and other initiative-related expenses		(4,191	)
	Total payments		(4,811	)
	Facilities consolidation accrual balance as of December 30, 2012	$	674
	Payments:
	Employee termination benefits		(475	)
	Moving, professional fees and other initiative-related expenses		(107	)
	Total payments		(582	)
	Facilities consolidation accrual balance as of December 29, 2013	$	92
OrthoHelix [Member]	'
Activity in Restructuring Accrual	'
	Activity in the restructuring accrual is presented in the following table (in thousands):
	OrthoHelix restructuring accrual balance as of December 30, 2012	$	—
	Charges:
	Employee termination benefits		381
	Moving, professional fees and other initiative-related expenses		—
	Total charges		381
	Payments:
	Employee termination benefits		—
	Moving, professional fees and other initiative-related expenses		—
	Total payments		—
	OrthoHelix restructuring initiative accrual balance as of December 29, 2013	$	381

Selected_Quarterly_Information1

Selected Quarterly Information (unaudited) (Tables)	12 Months Ended
	Dec. 29, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Results of Operations	'
	The operating results for any quarter are not necessarily indicative of results for any future period.
		Year ended December 29, 2013
		Fourth			Third			Second			First
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share data)
	Revenue	$	83,392		$	66,747		$	78,135		$	82,685
	Cost of goods sold		21,267			18,972			22,309			23,624
	Gross profit		62,125			47,775			55,826			59,061
	Operating expenses:
	Selling, general and administrative		56,451			46,797			51,467			52,136
	Research and development		5,997			4,665			5,543			6,182
	Amortization of intangible assets		4,288			3,976			3,784			3,837
	Special charges		2,729			(3,918	)		3,408			1,519
	Total operating expenses		69,465			51,520			64,202			63,674
	Operating loss		(7,340	)		(3,745	)		(8,376	)		(4,613	)
	Consolidated net loss		(10,699	)		(6,292	)		(12,537	)		(6,898	)
	Net loss per share:
	basic and diluted	$	(0.22	)	$	(0.13	)	$	(0.28	)	$	(0.17	)
		Year ended December 30, 2012
		Fourth			Third			Second			First
		Quarter			Quarter			Quarter			Quarter
		(in thousands, except per share data)
	Revenue	$	79,033		$	58,015		$	66,014		$	74,458
	Cost of goods sold		26,974			15,730			18,098			21,116
	Gross profit		52,059			42,285			47,916			53,342
	Operating expenses:
	Selling, general and administrative		46,290			38,524			41,795			43,838
	Research and development		6,195			5,260			5,446			5,623
	Amortization of intangible assets		3,708			2,730			2,636			2,647
	Special charges		9,831			6,503			2,910			—
	Total operating expenses		66,024			53,017			52,787			52,108
	Operating loss		(13,965	)		(10,732	)		(4,871	)		1,234
	Consolidated net loss		(4,803	)		(11,681	)		(5,084	)		(176	)
	Net loss per share:
	basic and diluted	$	(0.12	)	$	(0.29	)	$	(0.13	)	$	(0.00	)

Business_Description_Additiona

Business Description - Additional Information (Detail)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

Mar. 07, 2011

Feb. 28, 2011

Dec. 29, 2013

Dec. 30, 2012

Jan. 01, 2012

Dec. 29, 2013

Dec. 30, 2012

Mar. 07, 2011

Feb. 28, 2011

Feb. 28, 2011

7-May-11

Feb. 28, 2011

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

EUR (€)

Underwriters discounts and commissions [Member]

Underwriters discounts and commissions [Member]

Additional offering cost [Member]

IPO [Member]

IPO [Member]

Office

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Description Of Business [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Local sales and distribution activities, number of offices

'

'

13

'

'

'

'

'

'

'

'

'

Stockholders' equity, reverse stock split

'

'

'3-to-1

'

'

'

'

'

'

'

'

'

Issuance of ordinary shares through IPO

'

'

'

'

'

48,508,612

41,728,257

'

'

'

721,274

8,750,000

Offering Price per share

'

'

'

'

'

€ 0.03

€ 0.03

'

'

'

$19

$19

Proceeds from issuance of ordinary shares

$12,800,000

$149,200,000

$78,952,000

'

$171,577,000

'

'

'

'

'

'

'

Offering cost

'

'

'

'

'

'

'

$900,000

$10,800,000

$6,200,000

'

'

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Significant Accounting Policies [Line Items]	'	'	'
Foreign currency transaction (loss) gain	($1,820,000)	($473,000)	$193,000
Costs related to shipping and handling of products included in selling, general and administrative expense	5,700,000	5,100,000	5,200,000
Allowance for doubtful accounts	5,080,000	4,846,000	'
Percentage of customers	10.00%	'	'
Expense for excess or obsolete inventory	8,400,000	8,200,000	5,000,000
Charges related to rationalization of products	'	3,000,000	'
Inventory held on consignment	47,800,000	44,500,000	'
Goodwill impairment loss	0	0	0
Impairment loss	0	4,700,000	0
Accrued interest and penalties	300,000	200,000	'
Developed technology [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Impairment charge	'	'	200,000
License intangibles [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Impairment charge	100,000	'	'
Facilities Consolidation Initiative [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Impairment charge	'	900,000	'
Surgical Instruments [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Impairment charge	0	1,000,000	0
Depreciation	13,900,000	12,400,000	11,000,000
Minimum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, estimated useful lives	'1 year	'	'
Minimum [Member] | Building and improvements [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of plant and properties	'5 years	'	'
Minimum [Member] | Machinery and equipment [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of plant and properties	'2 years	'	'
Minimum [Member] | Software and Software Development Costs [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, estimated useful lives	'3 years	'	'
Maximum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, estimated useful lives	'20 years	'	'
Maximum [Member] | Building and improvements [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of plant and properties	'39 years	'	'
Maximum [Member] | Machinery and equipment [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of plant and properties	'8 years	'	'
Maximum [Member] | Facilities Consolidation Initiative [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Impairment charge	$100,000	'	'
Maximum [Member] | Software and Software Development Costs [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Intangible assets, estimated useful lives	'10 years	'	'

Significant_Accounting_Policie4

Significant Accounting Policies - Inventory Balances Net of Reserves (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$6,840	$5,696
Work in process	9,171	4,933
Finished goods	71,000	76,068
Total	$87,011	$86,697

Significant_Accounting_Policie5

Significant Accounting Policies - Instruments Included in Long-Term Assets (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'	'
Instruments	$99,754	$85,869
Instruments in progress	23,990	18,171
Accumulated depreciation	-60,689	-52,646
Instruments, net	$63,055	$51,394

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012	Jan. 01, 2011
In Thousands, unless otherwise specified
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	$56,784	$31,108	$54,706	$24,838
Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	56,784	31,108	'	'
Contingent consideration	-12,956	-15,265	'	'
Derivative asset	238	274	'	'
Total, net	44,066	16,117	'	'
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	56,784	31,108	'	'
Contingent consideration	'	'	'	'
Derivative asset	'	'	'	'
Total, net	56,784	31,108	'	'
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	'	'	'	'
Contingent consideration	'	'	'	'
Derivative asset	238	274	'	'
Total, net	238	274	'	'
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	'	'	'	'
Contingent consideration	-12,956	-15,265	'	'
Derivative asset	'	'	'	'
Total, net	($12,956)	($15,265)	'	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 29, 2013

Dec. 30, 2012

Jan. 01, 2012

Dec. 29, 2013

Oct. 04, 2012

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 30, 2012

Minimum [Member]

Maximum [Member]

Maximum [Member]

Facilities Consolidation Initiative [Member]

Facilities Consolidation Initiative [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Other Observable Inputs (Level 2) [Member]

Ortho Helix [Member]

Distributor in Belgium and Luxembourg [Member]

Distributor in Belgium and Luxembourg [Member]

Distributor in the United States [Member]

Distributor in Australia [Member]

OrthoHelix [Member]

Maximum [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of Derivative asset

'

'

'

'

'

'

'

'

$200,000

$300,000

'

'

'

'

'

'

Foreign exchange gain (loss) related to derivatives

'

'

'

'

'

'

'

'

400,000

300,000

'

'

'

'

'

'

Contingent consideration related to acquisition

'

'

'

'

20,000,000

'

'

'

'

'

10,400,000

500,000

700,000

1,900,000

200,000

14,500,000

Discount rate, Percentage

'

8.00%

'

8.00%

'

11.00%

'

'

'

'

'

'

'

'

'

'

Interest expense on the accretion of the contingent consideration

1,100,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transfers between levels

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible impairment

0

4,700,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges

'

'

'

'

'

'

900,000

100,000

'

'

'

'

'

'

'

'

Lease termination costs

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sublease termination liability

12,956,000

15,265,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term and long term debt

$69,100,000

$120,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Summary of Contingent Consideration Liability (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012
Debt Instrument Fair Value Carrying Value [Abstract]	'	'
Additions	$3,329	'
Fair value adjustments	-5,140	'
Settlements	-1,640	'
Interest accretion	1,132	'
Foreign currency translation	10	'
Contingent consideration at December 29, 2013	$12,956	$15,265

Business_Combination_Additiona

Business Combination - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 30, 2012

Sep. 30, 2012

Jul. 01, 2012

Apr. 01, 2012

Dec. 29, 2013

Dec. 30, 2012

Jan. 01, 2012

Oct. 04, 2012

Oct. 04, 2012

Dec. 29, 2013

Dec. 30, 2012

Maximum [Member]

OrthoHelix [Member]

OrthoHelix [Member]

OrthoHelix [Member]

Business Acquisition Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total preliminary purchase price

$152,596,000

'

'

'

'

'

'

'

$152,596,000

'

'

'

$152,600,000

'

'

Acquisition completion date

'

'

'

'

'

'

'

'

'

'

'

'

'

4-Oct-12

'

Capital stock acquired, percentage

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

Cash paid for acquisition

'

'

'

'

'

'

'

'

'

'

'

'

100,400,000

'

'

Value of stock given for acquisition

'

'

'

'

'

'

'

'

'

'

'

'

38,000,000

'

'

Fair Value of Contingent Consideration related to acquisition as of acquisition date

'

'

'

'

'

'

'

'

'

'

'

'

14,200,000

'

'

Gross contingent consideration

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

Purchase price allocated to goodwill

105,904,000

'

'

'

'

'

'

'

105,904,000

'

'

'

105,900,000

'

'

In-process research and development

3,500,000

'

'

'

3,500,000

'

'

'

3,500,000

3,500,000

'

'

'

'

'

Discount rate, Percentage

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

Revenue

83,392,000

66,747,000

78,135,000

82,685,000

79,033,000

58,015,000

66,014,000

74,458,000

310,959,000

277,520,000

261,191,000

'

'

'

8,000,000

Net loss related to operations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,800,000

Business_Combination_Schedule_

Business Combination - Schedule of Preliminary Allocation of Purchase Price (Detail) (USD $)	Dec. 29, 2013
In Thousands, unless otherwise specified
Business Combinations [Abstract]	'
Goodwill	$105,904
Other intangible assets	40,600
Tangible assets acquired and liabilities assumed:	'
Accounts receivable	4,330
Inventory	12,033
Other assets	776
Instruments, net	4,475
Accounts payable and accrued liabilities	-3,606
Deferred income taxes	-11,900
Other long-term debt	-16
Total purchase price	$152,596

Business_Combination_Summary_o

Business Combination - Summary of Identifiable Intangible Assets and their Estimated Useful Lives at Acquisition (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012	Dec. 29, 2013	Dec. 29, 2013	Dec. 29, 2013	Dec. 29, 2013
In Thousands, unless otherwise specified			Developed technology [Member]	In-process research and development [Member]	Trademarks and trade names [Member]	Non-compete agreements [Member]
Identifiable Intangible Assets Acquired [Line Items]	'	'	'	'	'	'
Developed technology	'	'	$35,500	'	'	'
In-process research and development	3,500	3,500	'	3,500	'	'
Trademarks and trade names	'	'	'	'	1,500	'
Non-compete agreements	'	'	'	'	'	100
Total identifiable intangible assets	$40,600	'	'	'	'	'
Estimated useful life of intangible assets	'	'	'10 years	'0 years	'3 years	'3 years

Business_Combination_Pro_forma

Business Combination - Pro forma Results of Operations (Detail) (USD $)	12 Months Ended
	Dec. 30, 2012	Jan. 01, 2012
Business Combinations [Abstract]	'	'
Revenue	$298,051	$283,370
Net loss	($31,390)	($43,155)
Basic and diluted net loss per share	($0.75)	($1.07)

Property_Plant_and_Equipment_P

Property, Plant and Equipment - Property, Plant and Equipment Balances (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Property Plant And Equipment Useful Life And Values [Abstract]	'	'
Land	$1,886	$1,830
Building and improvements	14,255	12,908
Machinery and equipment	31,192	25,767
Furniture, fixtures and office equipment	29,371	26,541
Software	5,511	4,729
Construction in progress	5,628	2,148
Property, plant, and equipment, gross	87,843	73,923
Accumulated depreciation	-44,349	-36,772
Property, plant and equipment, net	$43,494	$37,151

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation expense recorded on property, plant and equipment	$6,800,000	$6,100,000	$6,000,000
Impairment charge related to OrthoHelix integration	140,000	2,041,000	'
Fixed asset impairments related to the company's facilities	'	900,000	'
Ortho Helix [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Impairment charge related to OrthoHelix integration	100,000	'	'
Computer Software, Intangible Asset [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Software development costs	5,600,000	'	'
Europe [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Impairment charge related to distribution channel changes	'	$100,000	'

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Goodwill, Beginning balance	$239,804	$130,544
Contingent payment on acquisition	'	1,193
Goodwill acquired in acquisitions	8,239	106,654
Foreign currency translation	3,497	1,413
Goodwill, Ending balance	$251,540	$239,804

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Goodwill qualified for future tax deductions	$16,800,000	'	'	'	'	'	'	'	$16,800,000	'	'
Acquired assets of distributor	'	'	'	'	'	'	'	'	2,935,000	1,410,000	3,142,000
Distributor acquired earn out	'	'	'	'	'	'	'	'	'	1,000,000	'
Increase in intangible assets	'	'	'	'	'	'	'	'	'	3,000,000	'
Increase in goodwill	'	'	'	'	'	'	'	'	'	800,000	'
Additional Intangible assets recorded	'	'	'	'	'	'	'	'	'	40,600,000	'
In-process research and development	3,500,000	'	'	'	3,500,000	'	'	'	3,500,000	3,500,000	'
Additional goodwill recorded	'	'	'	'	'	'	'	'	8,239,000	106,654,000	'
Total amortization expense for finite-lived intangible assets	4,288,000	3,976,000	3,784,000	3,837,000	3,708,000	2,730,000	2,636,000	2,647,000	15,885,000	11,721,000	11,282,000
Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Finite-lived intangible assets useful life	'	'	'	'	'	'	'	'	'1 year	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Finite-lived intangible assets useful life	'	'	'	'	'	'	'	'	'20 years	'	'
Licenses [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Impairment charges	'	'	'	'	'	'	'	'	100,000	4,700,000	200,000
Canada [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Acquired assets of distributor	'	'	'	'	'	'	'	'	3,300,000	'	'
Distributor acquired earn out	'	'	'	'	'	'	'	'	500,000	'	'
Increase in goodwill	'	'	'	'	'	'	'	'	300,000	'	'
Canada [Member] | Customer relationships [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Increase in intangible assets	'	'	'	'	'	'	'	'	500,000	'	'
United Kingdom {Member}	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Acquired assets of distributor	'	'	'	'	'	'	'	'	1,000,000	'	'
Distributor acquired earn out	'	'	'	'	'	'	'	'	100,000	'	'
United Kingdom {Member} | Customer relationships [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Increase in intangible assets	'	'	'	'	'	'	'	'	100,000	'	'
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Increase in goodwill	'	'	'	'	'	'	'	'	6,700,000	'	'
United States [Member] | Non Compete Agreement [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Additional Intangible assets recorded	'	'	'	'	'	'	'	'	2,200,000	'	'
Australia [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Acquired assets of distributor	'	'	'	'	'	'	'	'	2,600,000	'	'
Distributor acquired earn out	'	'	'	'	'	'	'	'	200,000	'	'
Increase in goodwill	'	'	'	'	'	'	'	'	1,400,000	'	'
Australia [Member] | Non Compete Agreement [Member]	'	'	'	'	'	'	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Increase in intangible assets	'	'	'	'	'	'	'	'	$100,000	'	'

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Components of Identifiable Intangible Assets (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	$198,359	$189,626
Accumulated Amortization	-80,751	-63,032
Net Value	117,608	126,594
Tradename [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	9,960	9,492
Accumulated Amortization	'	'
Net Value	9,960	9,492
Developed technology [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	112,782	108,274
Accumulated Amortization	-44,161	-34,114
Net Value	68,621	74,160
Customer relationships [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	61,783	59,212
Accumulated Amortization	-30,155	-24,634
Net Value	31,628	34,578
Licenses [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	6,810	5,525
Accumulated Amortization	-4,004	-2,927
Net Value	2,806	2,598
In-process research and development [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	400	3,200
Accumulated Amortization	'	'
Net Value	400	3,200
Other [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross Value	6,624	3,923
Accumulated Amortization	-2,431	-1,357
Net Value	$4,193	$2,566

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets - Weighted Average Amortization Period by Major Intangible Asset Class (Detail)	12 Months Ended
	Dec. 29, 2013
Developed technology [Member]	'
Expected Amortization Expense Of Finite Lived Intangible Assets [Line Items]	'
Weighted-Average Amortization Period	'12 years
Customer relationships [Member]	'
Expected Amortization Expense Of Finite Lived Intangible Assets [Line Items]	'
Weighted-Average Amortization Period	'13 years
Licenses [Member]	'
Expected Amortization Expense Of Finite Lived Intangible Assets [Line Items]	'
Weighted-Average Amortization Period	'5 years
In-process research and development [Member]	'
Expected Amortization Expense Of Finite Lived Intangible Assets [Line Items]	'
Weighted-Average Amortization Period	'0 years
Large joints and other [Member]	'
Expected Amortization Expense Of Finite Lived Intangible Assets [Line Items]	'
Weighted-Average Amortization Period	'3 years

Goodwill_and_Other_Intangible_6

Goodwill and Other Intangible Assets - Estimated Annual Amortization Expense (Detail) (USD $)	Dec. 29, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014	$16,866
2015	16,420
2016	14,213
2017	13,299
2018	$12,475

Accrued_Liabilities_Schedule_o

Accrued Liabilities - Schedule of Accrued Liabilities (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Accrued payroll and related expenses	$21,499	$16,521
Accrued royalties	9,169	9,001
Accrued sales and use tax	4,727	2,022
Accrued agent commissions	4,554	5,266
Other accrued liabilities	10,765	11,599
Accrued Liabilities and Other Liabilities, Total	$50,714	$44,410

LongTerm_Debt_Summary_of_Debt_

Long-Term Debt - Summary of Debt (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Lines of credit and overdraft arrangements	'	$1,000
Mortgages	4,993	3,719
Bank term debt	61,769	113,135
Shareholder debt	2,319	2,198
Total debt	69,081	120,052
Less current portion	-1,438	-4,595
Long-term debt	$67,643	$115,457

LongTerm_Debt_Schedule_of_Aggr

Long-Term Debt - Schedule of Aggregate Maturities of Debt (Detail) (USD $)	Dec. 29, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2014	$1,438
2015	1,275
2016	1,447
2017	61,406
2018	649
Thereafter	$2,866

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 29, 2013

Dec. 30, 2012

Jan. 01, 2012

Jan. 01, 2012

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 29, 2013

Jun. 30, 2013

Dec. 29, 2013

Jun. 30, 2013

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

Dec. 31, 2008

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 30, 2012

Dec. 29, 2013

Dec. 29, 2013

European Subsidiaries [Member]

Term Debt [Member]

Term Debt [Member]

Term Debt [Member]

Term Debt [Member]

Term Debt [Member]

Term Debt [Member]

Term Debt [Member]

Term Debt [Member]

Shareholder Debt [Member]

Shareholder Debt [Member]

Shareholder Debt [Member]

Shareholder Debt [Member]

Shareholder Debt [Member]

Line of Credit [Member]

Line of Credit [Member]

Mortgage Backed Securities [Member]

Mortgage Backed Securities [Member]

Mortgage Backed Securities [Member]

Mortgage Backed Securities [Member]

Senior secured term loan facility one [Member]

Senior secured term loan facility one [Member]

Senior secured term loan facility two [Member]

Senior secured term loan facility two [Member]

Senior secured term loan facility two [Member]

Senior secured term loan facility two [Member]

Parent [Member]

Director [Member]

Director [Member]

Senior Secured Revolving Credit Facility [Member]

Senior Secured Revolving Credit Facility [Member]

Minimum [Member]

Maximum [Member]

Denominated in Dollars [Member]

Denominated in Euros [Member]

Denominated in Euros [Member]

U.S. Dollar Denominated Loan [Member]

Debt Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior secured revolving credit facility denominated in Dollars, Euros, Pounds, Sterling and Yen aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$30,000,000

'

'

'

'

'

Interest spread on LIBOR

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

Debt maturity date

'

'

'

'

'

'

'October 2017

'

'October 2017

'

'

'

'

'

'

'

'

'October 2017

'

'

'

'

'

Borrowings

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

1,000,000

'

'

'

'

Debt interest rate description

'

'

'

'

'The U.S. dollar denominated term facility bears interest at (a)B the alternate base rate (if denominated in U.S. dollars), equal to the greatest of (i)B the prime rate in effect on such day, (ii)B the federal funds rate in effect on such day plus 1/2 of 1%, and (iii)B the adjusted LIBO rate, with a floor of 1% (as defined in the Companybs new credit agreement) plus 1%, plus in the case of each of (i)-(iii)B above, an applicable rate of 2.00% or 2.25% (depending on the Companybs total net leverage ratio as defined in the credit agreement), or (b)B in the case of a eurocurrency loan (as defined in the Companybs credit agreement), at the applicable adjusted LIBO rate for the relevant interest period plus an applicable rate of 3.00% or 3.25% (depending on the Companybs total net leverage ratio), plus the mandatory cost (as defined in the Companybs credit agreement) if such loan is made in a currency other than U.S. dollars or from a lending office in the United Kingdom or a participating member state (as defined in the Companybs credit agreement). Under the Euro denominated term facility, (a)B alternate base rate loans bear interest at the alternate base rate plus the applicable rate, which is 3.00% or 3.25% (depending on the Companybs total net leverage ratio) and (b)B eurocurrency loans bear interest at the adjusted LIBO rate for the relevant interest period, plus an applicable rate, which is 4.00% or 4.25% (depending on the Companybs total net leverage ratio), plus the mandatory cost, if applicable.

'

'

'

'

'

'

'

'

'

'

'

'

'Funds under the revolving credit facility bear at (a) the alternate base rate (if denominated in U.S. dollars), equal to the greatest of (i) the prime rate in effect on such day, (ii) the federal funds rate in effect on such day plus 1/2 of 1%, and (iii) the adjusted LIBO rate plus 1%, plus in the case of each of (i)-(iii) above, an applicable rate of 2.00% or 2.25% (depending on the Companybs total net leverage ratio as defined in the Companybs credit agreement), or (b) in at the applicable adjusted LIBO rate for the relevant interest period plus an applicable rate of 3.00% or 3.25% (depending on the Companybs total net leverage ratio), plus the mandatory cost (as defined in the Companybs credit agreement) if such loan is made in a currency other than U.S. dollars or from a lending office in the United Kingdom or a participating member state (as defined in the Companybs credit agreement). Additionally, the Company is subject to a 0.5% interest rate related to the unfunded balance on the line of credit.

'

'

'

'

'

Additional Interest rate on unfunded balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

Loss on extinguishment of debt

-1,127,000

-593,000

-29,475,000

-600,000

'

'

'

'

'

-1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Mortgage outstanding amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

3,700,000

'

'

Mortgage bears fixed annual interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.55%

4.90%

Credit agreement amount

'

'

'

'

115,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior secured loan

60,874,000

111,559,000

'

'

'

'

'

75,000,000

'

'

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Senior secured term loan facility repayment

'

'

'

'

'

'

'

'

'

40,000,000

'

10,500,000

'

'

'

'

'

'

'

'

'

'

'

Amortization of the debt discount

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital leases included in term debt

'

'

'

'

900,000

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan payable

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

2,200,000

'

'

'

'

'

'

'

'

'

Variable interest rate on three-month euro

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

Interest rate description

'

'

'

'

'

'

'

'

'

'

'

'

'Interest on the debt is variable based on three-month Euro Libor rate plus 0.5%

'

'

'

'

'

'

'

'

'

'

Percentage of ownership interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51.00%

49.00%

'

'

'

'

'

'

'

Borrowings from board of director

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,200,000

'

'

'

'

'

'

LongTerm_Debt_Summary_of_Borro

Long-Term Debt - Summary of Borrowings (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Debt And Capital Lease Obligations [Line Items]	'	'
Debt discount	($3,157)	($5,138)
Total Term Debt, net of deferred financing costs	60,874	111,559
U.S. Dollar Term Loan [Member]	'	'
Debt And Capital Lease Obligations [Line Items]	'	'
Total Term Debt, net of deferred financing costs	64,031	75,925
Euro Term Loan [Member]	'	'
Debt And Capital Lease Obligations [Line Items]	'	'
Total Term Debt, net of deferred financing costs	'	$40,772

Retirement_and_Postretirement_1

Retirement and Postretirement Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Postemployment Benefits [Abstract]	'	'	'
Plan assets associated with defined-benefit plan	$0	'	'
Liability recorded for future obligation under the plan	2.8	2.5	'
Government mandated discount rate	3.00%	2.80%	4.70%
Unrealized gain (loss) recorded as a component of other comprehensive loss	$0.10	($0.90)	'

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012
Offsetting [Abstract]	'	'
Foreign currency forward contracts outstanding, Fair value amount	$0.20	'
Gain related to forward currency contracts	$0.40	$0.30

Income_Taxes_Components_of_Ear

Income Taxes - Components of Earnings (Loss) Before Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Income Tax Disclosure [Abstract]	'	'	'
United States loss	($33,204)	($19,858)	($2,631)
Rest of the world loss	-873	-12,821	-36,249
Loss before income taxes	($34,077)	($32,679)	($38,880)

Income_Taxes_Summary_of_Income

Income Taxes - Summary of Income Tax Benefit (Provision) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Components Of Income Tax Expense Benefit [Line Items]	'	'	'
Deferred (provision) benefit	$1,258	$13,608	$11,891
Total income tax (provision) benefit	-2,349	10,935	8,424
Current Period [Member]	'	'	'
Components Of Income Tax Expense Benefit [Line Items]	'	'	'
United States	-94	-150	-327
Rest of the world	($3,513)	($2,523)	($3,140)

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Tax Rate (Detail)	12 Months Ended
	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Income Tax Disclosure [Abstract]	'	'	'
Income tax provision at U.S. statutory rate	34.00%	34.00%	34.00%
Release of valuation allowance	3.30%	32.80%	'
Change in valuation allowance	-38.60%	-33.40%	-10.10%
Tax benefit from disregarded entity	1.80%	1.70%	6.40%
State and local taxes	-4.70%	2.60%	-0.40%
Tax deductible IPO costs	2.00%	1.70%	'
Other foreign taxes	-3.50%	-3.50%	-2.00%
Unrecognized interest deduction	'	'	-0.50%
Contingent consideration adjustment to market value	4.10%	'	'
Stock option cancellation	-8.10%	'	'
Impact of foreign income tax rates	2.10%	-2.50%	-6.90%
Non-deductible expenses	-1.10%	-1.80%	-0.60%
Other	1.80%	1.90%	1.70%
Total	-6.90%	33.50%	21.60%

Income_Taxes_Components_of_Def

Income Taxes - Components of Deferred Taxes (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'	'
Net operating loss and tax credit carryforwards	$41,456	$27,924	'
Inventory	7,294	4,960	'
Exchange rate changes	102	223	'
Stock options	7,082	9,715	'
Accruals and other provisions	6,161	5,067	'
Total deferred tax assets	62,095	47,889	'
Less: valuation allowance	-40,441	-30,011	-29,800
Total deferred tax assets after valuation allowance	21,654	17,878	'
Intangible assets	-33,553	-33,248	'
Depreciation	-3,342	-2,033	'
Total deferred tax liabilities	-36,895	-35,281	'
Total net deferred tax liabilities	($15,241)	($17,403)	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'
Valuation allowance recorded	$40,441,000	$30,011,000	$29,800,000
Recognition of valuation allowance as tax expense	10,400,000	200,000	2,900,000
Increase in valuation allowance	11,500,000	10,900,000	'
Net operating loss carryforwards	128,800,000	'	'
Net operating loss carryforwards with no expiration date	6,000,000	'	'
Net operating loss remaining carry forwards expiration date	'Expiration dates between 2015 and 2033	'	'
Net operating loss remaining carry forwards expiration start date	'2015	'	'
Net operating loss remaining carry forwards expiration start End date	'2033	'	'
Long term liability related to tax position in subsidiaries	3,100,000	2,600,000	'
Unrecognized tax benefits, if recognized would affect tax rate	6,400,000	'	'
US Subsidiaries [Member]	'	'	'
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'
Net operating loss carryforwards	82,000,000	'	'
European Subsidiaries [Member]	'	'	'
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'
Net operating loss carryforwards	50,000,000	'	'
OrthoHelix [Member]	'	'	'
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'
Deferred tax Liabilities recorded in connection with the acquisition	'	11,900,000	'
Deferred tax liability related to amortizable intangible asset	1,100,000	10,700,000	'
Deferred tax liability related to indefinite-lived acquired in-process research and development asset	'	$1,200,000	'

Income_Taxes_Reconciliation_of1

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012
Income Tax Disclosure [Abstract]	'	'
Gross unrecognized tax benefits, Beginning Balance	$7,909	$5,232
Increase for tax positions in prior years	58	2,282
Decrease for tax positions in prior years	'	'
Settlements	-2,094	'
Increase for tax positions in current year	307	306
Foreign currency translation	236	89
Gross unrecognized tax benefits, Ending Balance	$6,416	$7,909

Recovered_Sheet1

Capital Stock And Earnings Per Share - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Ordinary shares, issued	48,508,612	41,728,257	'
Ordinary shares, outstanding	48,508,612	41,728,257	'
Net proceeds from issuance of common stock	$78.70	'	'
Purchase ordinary shares outstanding	2,600,000	3,800,000	4,200,000
Restricted stock units outstanding	600,000	400,000	200,000
Total outstanding options and restricted stock units	3,200,000	4,200,000	4,400,000
Secondary Offering [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Secondary offering for the issuance of common stock	5,175,000	'	'

Segment_and_Geographic_Data_Ad

Segment and Geographic Data - Additional Information (Detail)	12 Months Ended
	Dec. 29, 2013
	Segment
Segment Reporting [Abstract]	'
Reportable segment	1

Segment_and_Geographic_Data_Su

Segment and Geographic Data - Summary of Revenue by Geographic Region (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$83,392	$66,747	$78,135	$82,685	$79,033	$58,015	$66,014	$74,458	$310,959	$277,520	$261,191
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	182,104	156,750	141,496
France [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	58,173	52,737	55,438
Other International [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	$70,682	$68,033	$64,257

Segment_and_Geographic_Data_Su1

Segment and Geographic Data - Summary of Revenue by Product Category (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$83,392	$66,747	$78,135	$82,685	$79,033	$58,015	$66,014	$74,458	$310,959	$277,520	$261,191
Upper extremity joints and trauma [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	184,457	175,242	164,064
Lower extremity joints and trauma [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	58,747	34,109	26,033
Sports medicine and biologics [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	14,752	15,526	14,779
Total extremities [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	257,956	224,877	204,876
Large joints and other [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	$53,003	$52,643	$56,315

Segment_and_Geographic_Data_Su2

Segment and Geographic Data - Summary of Long Lived Tangible Assets Including Instruments and Property Plant and Equipment (Detail) (USD $)	Dec. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Long-lived assets	$106,549	$88,545
United States [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Long-lived assets	40,032	31,342
France [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Long-lived assets	45,909	39,764
Other International [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Long-lived assets	$20,608	$17,439

Leases_Future_Minimum_Rental_C

Leases - Future Minimum Rental Commitments Under Non-cancelable Operating Leases (Detail)	Dec. 29, 2013	Dec. 29, 2013
In Thousands, unless otherwise specified	USD ($)	EUR (€)
Leases [Abstract]	'	'
2014	$5,410	'
2015	4,500	'
2016	3,535	'
2017	3,286	'
2018	3,050	'
Thereafter	8,362	'
Total	$28,143	€ 4,300

Leases_Additional_Information_

Leases - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Future Minimum Lease Payments Under Capital Leases And Operating Leases For Continuing Operations [Line Items]	'	'	'
Rent Expense	$5.80	$4.80	$4
Machinery and equipment [Member]	'	'	'
Future Minimum Lease Payments Under Capital Leases And Operating Leases For Continuing Operations [Line Items]	'	'	'
Capital leased assets, Gross	2.5	3.4	'
Accumulated depreciation	0.8	0.8	'
Capital leased assets, Net	$1.70	$2.60	'
Minimum [Member]	'	'	'
Future Minimum Lease Payments Under Capital Leases And Operating Leases For Continuing Operations [Line Items]	'	'	'
Operating leases maturity dates	'2014	'	'
Maximum [Member]	'	'	'
Future Minimum Lease Payments Under Capital Leases And Operating Leases For Continuing Operations [Line Items]	'	'	'
Operating leases maturity dates	'2022	'	'

Leases_Future_Lease_Payments_U

Leases - Future Lease Payments Under Capital Leases (Detail) (USD $)	Dec. 29, 2013
In Thousands, unless otherwise specified
Leases [Abstract]	'
2014	$461
2015	269
2016	114
2017	70
Total minimum lease payments	914
Less amount representing interest	-67
Present value of minimum lease payments	847
Current portion	-448
Long-term portion	$399

Certain_Relationships_and_Rela1

Certain Relationships and Related-Party Transactions - Additional Information (Detail)

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

Jul. 29, 2008

Dec. 29, 2013

Dec. 29, 2013

Dec. 30, 2012

Jan. 01, 2012

Jul. 29, 2008

Dec. 29, 2013

Dec. 29, 2007

Dec. 29, 2013

Aug. 18, 2012

Dec. 29, 2013

Aug. 18, 2012

Dec. 29, 2013

Jul. 29, 2008

Jul. 29, 2008

Sep. 03, 2008

Dec. 29, 2013

Jul. 29, 2008

Jul. 29, 2008

Dec. 29, 2013

Dec. 29, 2013

Dec. 29, 2013

EUR (€)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

Mr. Tornier [Member]

Mr. Tornier [Member]

Mr. Tornier [Member]

Animus SCI [Member]

Animus SCI [Member]

Balux SCI [Member]

Balux SCI [Member]

SCI Calyx [Member]

SCI Calyx [Member]

SCI Calyx [Member]

SCI Calyx [Member]

SCI Calyx [Member]

SCI Calyx [Member]

SCI Calyx [Member]

Manufacturing Facility [Member]

Office Space [Member]

USD ($)

Tornier SAS [Member]

Tornier SAS [Member]

Tornier SAS [Member]

Tornier SAS [Member]

EUR (€)

EUR (€)

USD ($)

EUR (€)

Tornier SAS [Member]

Tornier SAS [Member]

Tornier SAS [Member]

Mr. Tornier [Member]

Mr. Tornier [Member]

Mr. Tornier [Member]

Mr. Tornier [Member]

EUR (€)

EUR (€)

EUR (€)

EUR (€)

USD ($)

USD ($)

USD ($)

sqft

sqft

Schedule of Other Related Party Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Area of leased property

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55,000

52,000

Annual lease payments

'

$1,100,000

'

$1,600,000

$1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of formation

'

'

'

'

'

'

'

'

'

'

'

'

'

29-Jul-08

'

'

'

'

'

'

'

'

Percentage of ownership held by non controlling owners

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49.00%

'

'

'

Percentage of ownership held for subsidiary entity

'

'

'

'

'

'

'

'

'

'

'

'

'

51.00%

'

'

'

'

'

'

'

'

Initial Capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

Percentage of capital contributions

'

'

'

'

'

'

'

'

'

'

'

'

'

51.00%

'

'

'

'

49.00%

'

'

'

Manufacturing and office facility acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

6,100,000

'

'

'

'

'

'

'

'

Mortgage borrowings on real estate purchase

'

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

'

'

'

'

'

'

'

'

Loan from share holders

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

2,000,000

'

'

'

1,000,000

1,000,000

1,400,000

'

'

Annual interest rate on note issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'Three-month Euro Libor rate plus 0.5%

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

Lease agreement date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3-Sep-08

'

'

'

'

'

Lease expiring date

'

'

'

'

'

'

'

'

'

'

'

'

'2022

'

'

'2018

'

'

'

'

'

'

Annual rent payment

440,000

'

904,908

'

'

'

'

28,500

36,095

279,506

288,564

252,254

548,465

'

'

'

'

'

'

'

'

'

Future minimum payments under lease agreement

'

28,143,000

4,300,000

'

'

'

'

'

'

'

'

'

8,100,000

'

'

'

'

'

'

'

'

'

Related-party debt outstanding

'

'

'

'

'

'

$2,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012	Jan. 01, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based awards granted under Tornier N.V.2010 Incentive Plan	7,700,000	'	'	'
Service period	'4 years	'	'	'
Options expire period	'10 years	'	'	'
Total compensation expense	$8,300,000	$6,830,000	$6,547,000	'
Expense related to non-employee options	300,000	300,000	300,000	'
Additional expense recognized due to change in estimate	1,600,000	'	'	'
Capitalized cost	400,000	300,000	'	'
Weighted average fair value per share	$8.95	$8.55	'	$12.06
Total unrecognized compensation cost	8,200,000	'	'	'
Weighted-average service period	'1 year 6 months	'	'	'
Shares reserved for future compensation grants	2,100,000	2,500,000	'	'
Exercise prices per share for options outstanding range	$19.89	$18.23	$18.32	$17.02
Weighted average exercise price per share	$19.32	$18.45	$24.76	'
Non-employee options exercisable	177,013	'	'	'
Non-employee options exercised	26,007	'	'	'
Non-employee option forfeited	6,180	'	'	'
Non Employee Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average fair value per share	'	'	$9.74	'
Granted options to purchase ordinary shares	0	0	74,667	'
Weighted average exercise price per share	'	'	$19.39	'
Employee And Non Employee Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total compensation expense	5,300,000	5,000,000	5,800,000	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total compensation expense	$3,000,000	$1,800,000	$700,000	'
Vesting period of stock units awards	'4 years	'	'	'
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Exercise prices per share for options outstanding range	$13.39	$27.31	'	'
Minimum [Member] | Non Employee Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period of stock units awards	'2 years	'	'	'
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Exercise prices per share for options outstanding range	$13.39	$27.31	'	'
Maximum [Member] | Non Employee Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Vesting period of stock units awards	'4 years	'	'	'

ShareBased_Compensation_Summar

Share-Based Compensation - Summary of Allocation of Share-Based Compensation (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share-based compensation expense	$8,300	$6,830	$6,547
Cost of goods sold [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share-based compensation expense	658	864	841
Selling, general and administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share-based compensation expense	6,955	5,477	5,263
Research and development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated share-based compensation expense	$687	$489	$443

ShareBased_Compensation_ShareB

Share-Based Compensation - Share-Based Compensation Weighted-Average Assumptions (Detail)	12 Months Ended
	Dec. 29, 2013	Jan. 01, 2012	Jan. 01, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Risk-free interest rate	1.70%	0.90%	2.10%
Expected life in years	'6 years 1 month 6 days	'6 years 1 month 6 days	'6 years 1 month 6 days
Expected volatility	46.60%	48.10%	48.60%
Expected dividend yield	0.00%	0.00%	0.00%

ShareBased_Compensation_Summar1

Share-Based Compensation - Summary of Employee Stock Option Activity (Detail) (USD $)	12 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012	Jan. 01, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'
Ordinary shares outstanding, beginning balance	3,782	3,896	3,532	'
Weighted-average exercise price outstanding, beginning balance	$18.23	$18.32	$17.02	'
Ordinary shares, Granted	643	626	647	'
Ordinary shares, Exercised	-1,454	-426	-210	'
Ordinary shares, Forfeited or Expired	-543	-314	-73	'
Ordinary shares outstanding, ending balance	2,428	3,782	3,896	3,532
Ordinary shares outstanding exercisable at period end	1,236	'	'	'
Weighted-average exercise price, Granted	$19.32	$18.45	$24.76	'
Weighted-average exercise price, Exercised	$14.38	$16.56	$15.02	'
Weighted-average exercise price, Forfeited or Expired	$22.51	$22.33	$20.96	'
Weighted-average exercise price outstanding, ending balance	$19.89	$18.23	$18.32	$17.02
Weighted-average exercise price, exercisable at period end	$20.03	'	'	'
Weighted-average remaining contractual life outstanding	'7 years 6 months	'6 years 4 months 24 days	'6 years 10 months 24 days	'7 years 4 months 24 days
Weighted-average remaining contractual life exercisable at period end	'6 years 2 months 12 days	'	'	'
Aggregate intrinsic value outstanding, beginning balance	($7.30)	($3.80)	$19.40	'
Aggregate intrinsic value outstanding, ending balance	-3.9	-7.3	-3.8	19.4
Aggregate intrinsic value, exercisable at period end	($2.10)	'	'	'

Share_Based_Compensation_Summa

Share Based Compensation - Summary of Activities Related to Restricted Stock Units (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Restricted stock unit outstanding, beginning balance	422	207	'
Restricted Stock Unit, Granted	323	305	221
Restricted stock unit, Vested	-97	-55	-7
Restricted stock unit, Cancelled	-75	-35	-7
Restricted stock unit outstanding, ending balance	573	422	207
Weighted-average grant date fair value outstanding, beginning balance	$20.57	$25.10	'
Weighted-average grant date fair value, Granted	$19.25	$18.51	$25.06
Weighted-average grant date fair value, Vested	$16.40	$20.21	$23.61
Weighted-average grant date fair value, Cancelled	$22.03	$24.01	$25.52
Weighted-average grant date fair value outstanding, ending balance	$19.54	$20.57	$25.10

Other_Non_Operating_Income_Add

Other Non- Operating Income - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 30, 2012	Jan. 01, 2012
Other Income And Expenses [Abstract]	'	'
Amount recognized in other non-operating income	$0.10	$1.30
Settlement of contingent liability	'	1
Gain on sale of non operating real estate	'	$0.30

Special_Charges_Schedule_of_Sp

Special Charges - Schedule of Special Charges (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Restructuring charges	'	'	'	'	'	'	'	'	'	$6,357	'
Acquisition, integration and distributor transition costs	'	'	'	'	'	'	'	'	7,143	4,920	'
Reduction in contingent consideration liability	'	'	'	'	'	'	'	'	-5,140	'	'
Legal settlements	'	'	'	'	'	'	'	'	1,214	'	'
Italy bad debt expense	'	'	'	'	'	'	'	'	'	2,001	'
Management exit costs	'	'	'	'	'	'	'	'	'	1,229	632
Intangible asset impairments	'	'	'	'	'	'	'	'	'	4,737	'
Other	'	'	'	'	'	'	'	'	'	'	260
Total	2,729	-3,918	3,408	1,519	9,831	6,503	2,910	'	3,738	19,244	892
OrthoHelix [Member]	'	'	'	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Restructuring charges	'	'	'	'	'	'	'	'	521	'	'
Reduction in contingent consideration liability	'	'	'	'	'	'	'	'	$5,140	'	'

Special_Charges_Additional_Inf

Special Charges - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
		Employees
Restructuring Cost and Reserve [Line Items]	'	'	'
Acquisition and Integration cost	$7,100,000	$3,500,000	'
Gain recognized on reversal of contingent consideration related to acquisition	-5,140,000	'	'
Legal charges	1,200,000	'	'
Facilities consolidation initiative costs	'	6,357,000	'
Intangible Impairment	'	4,737,000	'
Bad debt expense	'	2,001,000	'
Termination costs	'	1,400,000	'
Management exit costs	'	1,229,000	632,000
Facility closure costs	'	'	300,000
Impairment charges for fixed asset	140,000	2,041,000	'
Estimated employees affected under closure of plans	'	65	'
Chief Executive Officer and Chief Financial Officer [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Management exit costs	'	1,200,000	'
Minimum [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Reduce annual operating expenses	'	2,300,000	'
Maximum [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Reduce annual operating expenses	'	2,800,000	'
Employee termination benefits [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Facilities consolidation initiative costs	'	1,180,000	'
Impairment charges related to fixed assets [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Facilities consolidation initiative costs	'	872,000	'
Moving, professional fees and other initiative-related expenses [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Facilities consolidation initiative costs	'	4,305,000	'
OrthoHelix [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Gain recognized on reversal of contingent consideration related to acquisition	5,140,000	'	'
Facilities consolidation initiative costs	521,000	'	'
Employee termination benefits include severance and related retention	400,000	'	'
Impairment charges for fixed asset	100,000	'	'
OrthoHelix [Member] | Minimum [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Estimated restructuring cost	2,000,000	'	'
OrthoHelix [Member] | Maximum [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Estimated restructuring cost	$2,500,000	'	'

Special_Charges_Activity_in_Re

Special Charges - Activity in Restructuring Accrual (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	$6,357	'
Employee termination benefits [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	1,180	'
Moving, professional fees and other initiative-related expenses [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	4,305	'
OrthoHelix restructuring initiative [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	381	'	'
Payments for restructuring	'	'	'
Facility consolidation accrual, ending balance	381	'	'
OrthoHelix restructuring initiative [Member] | Employee termination benefits [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	381	'	'
Payments for restructuring	'	'	'
OrthoHelix restructuring initiative [Member] | Moving, professional fees and other initiative-related expenses [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	'	'
Payments for restructuring	'	'	'

Special_Charges_Amounts_Recogn

Special Charges - Amounts Recognized within Special Charges Related to Restructuring (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	$6,357	'
Employee termination benefits [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	1,180	'
Impairment charges related to fixed assets [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	872	'
Moving, professional fees and other initiative-related expenses [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	$4,305	'

Special_Charges_Activity_in_Fa

Special Charges - Activity in Facilities Consolidation Accrual (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	$6,357	'
Employee termination benefits [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	1,180	'
Moving, professional fees and other initiative-related expenses [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	4,305	'
Facilities Consolidation Initiative [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Facility consolidation accrual, beginning balance	674	'	'
Restructuring charges	'	6,357	'
Payments for restructuring	-582	-4,811	'
Facility consolidation accrual, ending balance	92	674	'
Facilities Consolidation Initiative [Member] | Employee termination benefits [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	1,180	'
Payments for restructuring	-475	-620	'
Facilities Consolidation Initiative [Member] | Moving, professional fees and other initiative-related expenses [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring charges	'	4,305	'
Payments for restructuring	($107)	($4,191)	'

Selected_Quarterly_Information2

Selected Quarterly Information - Summary of Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue	$83,392	$66,747	$78,135	$82,685	$79,033	$58,015	$66,014	$74,458	$310,959	$277,520	$261,191
Cost of goods sold	21,267	18,972	22,309	23,624	26,974	15,730	18,098	21,116	86,172	81,918	74,882
Gross profit	62,125	47,775	55,826	59,061	52,059	42,285	47,916	53,342	224,787	195,602	186,309
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Selling, general and administrative	56,451	46,797	51,467	52,136	46,290	38,524	41,795	43,838	206,851	170,447	161,448
Research and development	5,997	4,665	5,543	6,182	6,195	5,260	5,446	5,623	22,387	22,524	19,839
Amortization of intangible assets	4,288	3,976	3,784	3,837	3,708	2,730	2,636	2,647	15,885	11,721	11,282
Special charges	2,729	-3,918	3,408	1,519	9,831	6,503	2,910	'	3,738	19,244	892
Total operating expenses	69,465	51,520	64,202	63,674	66,024	53,017	52,787	52,108	248,861	223,936	193,461
Operating loss	-7,340	-3,745	-8,376	-4,613	-13,965	-10,732	-4,871	1,234	-24,074	-28,334	-7,152
Consolidated net loss	($10,699)	($6,292)	($12,537)	($6,898)	($4,803)	($11,681)	($5,084)	($176)	($36,426)	($21,744)	($30,456)
Net loss per share:	'	'	'	'	'	'	'	'	'	'	'
Basic and diluted	($0.22)	($0.13)	($0.28)	($0.17)	($0.12)	($0.29)	($0.13)	$0	($0.79)	($0.54)	($0.80)

Selected_Quarterly_Information3

Selected Quarterly Information - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'
Charges included in special charges	$2.70	($3.90)	$3.40	$1.50	$2.50	$2.90	$1.10
Acquired inventory fair value included in cost of goods sold	0.5	1.8	1.9	1.8	1.6	'	'
Inventory product rationalization charge	'	'	'	'	2.9	'	'
Tax benefit due to the reversal of valuation allowance from the acquisition	'	'	'	'	$10.70	'	'

Valuation_And_Qualifying_Accou

Valuation And Qualifying Accounts (Valuation And Qualifying Accounts) (Detail) (Detail) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 29, 2013	Dec. 30, 2012	Jan. 01, 2012
Allowance for Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Beginning Balance	($4,846)	($2,486)	($2,519)
Additions Charged to costs and Expenses	-1,220	-2,355	-775
Uncollectible amounts written off, net of recoveries	1,208	87	755
Effect of changes in foreign exchange rates	-222	-92	53
Ending Balance	($5,080)	($4,846)	($2,486)